<HTML>
<HEAD>
<TITLE>S-1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">
</div>

<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>



<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM S-1</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>GENERAL FORM FOR REGISTRATION OF SECURITIES OF SMALL BUSINESS<BR>
ISSUERS<BR>
Under Section&nbsp;12(G) of the Securities Exchange Act of 1933</B>
</DIV>

<DIV align="center" style="font-size: 22pt; margin-top: 12pt"><B><FONT style="border-bottom: 1px solid #000000">HEALTHCARE CORPORATION OF AMERICA</FONT></B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Name of Small Business Issuer in its Charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">NEW JERSEY
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">26 2071625</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp; &nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State of other jurisdictional
incorporation or organization)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employee Identification No.)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">2833</DIV>

<DIV align="center" style="font-size: 10pt"><DIV style="margin-top: 1px"><FONT style="border-top: 1px solid #000000">(Primary Standard Industrial Classification Code Number)</FONT></DIV></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Gary Sekulski, CEO and President, 36 Kevin Drive, Flanders, New Jersey 07836<BR>
Tel 973 796 4216</DIV>

<DIV align="center" style="font-size: 10pt"><DIV style="margin-top: 1px"><FONT style="border-top: 1px solid #000000">(Address , including zip code, and telephone number, including area code, of registrants&#146;</FONT></DIV>
principal executive offices)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Copy to<BR>
Joseph Drucker, Attorney, 43 Sawgrass Street, Jackson, New Jersey 08527<BR>
732 928 5965</DIV>

<DIV align="center" style="font-size: 10pt"><DIV style="margin-top: 1px"><FONT style="border-top: 1px solid #000000">(Name, address, including zip code, and telephone number, including area code, of agent for</FONT></DIV>
services)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Approximate date of commencement of proposed sale to the public: as soon as practicable after
this registration becomes effective.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If any of the securities being registered on this form are to be offered on a delayed or continuous
basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, check the following box. <FONT face="Wingdings">&#254;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)
under the Securities Act, check the following box and list the Securities Act Registration
statement number of earlier effective registration statement for the same offering. <FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act,
check the following box and list the Securities Act Registration statement number of earlier
effective registration statement for the same offering. <FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act,
check the following box and list the Securities Act Registration statement number of earlier
effective registration statement for the same offering. <FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">*Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.
(Check one):
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Large accelerated filer <FONT face="Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Accelerated filer <FONT face="Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Non-accelerated filer <FONT face="Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" nowrap>Smaller reporting company <FONT face="Wingdings">&#254;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" nowrap>(Do not check if a smaller reporting company)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">CALCULATION OF REGISTRATION FEE</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="54%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
</TR><TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="15" style="border-bottom: 3px double #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Proposed</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Proposed</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center">Title of</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">maximum</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">maximum</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center">securities</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Amount</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">offering</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Aggregate</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Amount of</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center">to be</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">to be</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Price</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">offering</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">registration</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center">registered</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">registered</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">per share</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">price</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">fee</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
                    <TD align="center" style="border-top: 2px solid #000000"><DIV style="margin-left:15px; text-indent:-15px">Common</DIV></TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 2px solid #000000">13,630,000</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 2px solid #000000">$0.50</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 2px solid #000000">$6,815,000</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>

<TD align="center" valign="top" style="border-top: 2px solid #000000">$380.28</TD>
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="15" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Up to 13,630,000 shares of our common stock may be sold by the selling shareholders to the public
at a fixed price of $0.50 per share until such time as the shares of our common stock are quoted on
the NASD Over-the Counter Bulletin Board (&#147;Board&#148;) or listed on an exchange. Although we intend to
apply for quotation of our common stock on the OTCBB, public trading of our common stock may never
materialize. If our common stock becomes quoted on the OTCBB, then the sale price to the public
will vary according to prevailing market prices or privately negotiated prices by the selling
shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Company hereby amends this registration statement on such date or dates as may be necessary to
delay its effective date until the Company shall file a further statement which specifically states
that this registration statement shall become effective on such date as the Commission, acting
pursuant to said Section 8(a) of the Securities Act of 1933 or until the registration statement
shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may
determine.
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt">PROSPECTUS SUBJECT TO COMPLETION, DRAFTED APRIL, 2009
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">HEALTH CARE CORPORATION OF AMERICA

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">This prospectus relates to the resale, form time to time, of up to 13,630,000 shares of our common
stock at $0.50 by the selling shareholders named in the &#147;Selling Shareholders&#148; section of this
prospectus. Healthcare Corporation of America will not receive any proceeds from this offering and
has not made any arrangements for the sale of these securities. See &#147;Risk Factors&#148; commencing on
page 8 for a full discussion of the risks involved in this offering.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3">Proceeds to Selling</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3" style="border-bottom: 1px solid #000000">Offering Price</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3" style="border-bottom: 1px solid #000000">Commissions</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3" style="border-bottom: 1px solid #000000">Shareholders</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Per Share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">6,815,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">6,815,000</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The information in this prospectus may be changed. We may amend or supplement this prospectus from
time to time by filing amendments or supplements as required. You should read the entire
prospectus and any amendments of supplements carefully before you make your investment decision.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">This prospectus is not an offer to sell our securities and it is not soliciting an offer to buy our
securities in any state where the offer or sale is not permitted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any
representation to the contrary is a criminal offence.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The selling stockholders or their permitted transferees or other successors in interest may, but
are not required to, sell their holdings at a fixed price of $0.50 per share until our shares are
quoted on the OTC Bulletin Board. Thereafter they may sell their holdings in a number of different
ways and at varying prices as determined by the prevailing market price for the shares or,
privately as negotiated prices. See &#147;Plan of Distribution&#148;
on Page 12 for a description of how
the selling stockholders may dispose of the shares covered by this prospectus. We do not know when
or in what amount the selling stockholders may offer the shares for sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We will not receive any of the proceeds from sales of shares made by the selling stockholders
pursuant to this prospectus. We have agreed to pay certain expenses related to the registration of
the shares pursuant to the registration statement of which this prospectus forms a part.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 10pt">These shares are presently not traded on any market or securities exchange. We cannot assure you
that a market maker will undertake to file the necessary documents with The Financial Industry
Regulatory Authority (FINRA&#148;) which operates the OTC Electronic Bulletin Board, nor can we assure
you that such an application for quotation will be approved.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">THE COMPANY IS CONSIDERED TO BE IN UNSOUND FINANCIAL CONDITION. PERSONS SHOULD NOT INVEST UNLESS
THEY CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENTS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">THE PURCHASE OF THE SECURITIES OFFERED THROUGH THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. YOU
SHOULD CAREFULLY CONSIDER THE FACTORS DESCRIBED IN THE &#147;RISK FACTORS&#148; SECTION BEGINNING ON PAGE 8
OF THIS PROSPECTUS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR
DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#101">PROSPECTUS SUMMARY</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#102">THE OFFERING</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#103">SUMMARY FINANCIAL INFORMATION</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#104">RISK FACTORS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#105">FORWARD-LOOKING STATEMENTS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#106">USE OF PROCEEDS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#107">DETERMINATION OF OFFERING PRICE</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#108">DILUTION</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#109">SELLING SECURITY HOLDERS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#110">PLAN OF DISTRIBUTION</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#111">SELLING SHAREHOLDER&#146;S &#147;UNDERWRITER&#148; STATUS: PROSPECTUS DELIVERY REQUIREMENT</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#112">LEGAL PROCEEDINGS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#113">DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#114">COMMITTEES OF THE BOARD OF DIRECTORS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#115">INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#116">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#117">DESCRIPTION OF CAPITAL STOCK</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#118">DIVIDEND POLICY</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#119">LEGAL MATTERS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#120">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#121">MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#122">EXPERTS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#123">INDEMNIFICATION</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#124">AVAILABLE INFORMATION</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#125">BUSINESS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#126">EXECUTIVE SUMMARY</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#127">STOCK ISSUANCES</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#128">DESCRIPTION OF SECURITIES</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#129">UNDERTAKINGS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#130">SIGNATURES</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#131">POWER OF ATTORNEY</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">FINANCIAL STATEMENTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">F-1</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y76306exv3w1.htm">EX-3.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y76306exv3w2.htm">EX-3.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y76306exv3w3.htm">EX-3.3</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y76306exv3w4.htm">EX-3.4</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y76306exv3w5.htm">EX-3.5</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y76306exv5w1.htm">EX-5.1</A></FONT></TD></TR>
</TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">You should rely only on the information contained in this prospectus and in any accompanying
prospectus supplement. We have not, and the Selling Shareholders have not, authorized anyone to
provide you with information different from the information contained in this prospectus. The
information in this prospectus is accurate only as of the date of this prospectus, regardless of
when this prospectus is delivered or when any dale of our common stock occurs.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left">
<A name="101"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PROSPECTUS SUMMARY</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following summary highlights selected information contained in this registration statement.
This summary does not contain all the information you should consider before purchasing the
securities from the selling shareholders. Before making an investment decision, you should read
the entire prospectus carefully including the &#147;RISK FACTORS&#148; SECTION, THE FINANCIAL STATEMENTS AND
THE NOTES TO THE FINANCIAL STATEMENTS. As used throughout this prospectus, the terms &#147;Healthcare,&#148;
the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Healthcare Corporation of America. All dollar
amounts in this prospectus are in U.S. dollars unless otherwise stated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">HCA is a product development and marketing company that has developed a new business model that
will reduce and control pharmacy costs for non-profit organizations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Healthcare Corporation of America was incorporated under the laws of New Jersey, February&nbsp;26, 2008.
As of the date specified all cash has been raised from the issuance of securities. $32,500 from
sale of shares through a Private Placement Memorandum Form&nbsp;D filing. $200,000 from a Stock Purchase
Agreement with First Time II LLC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our administrative office is located at 36 Kevin Drive, Flanders, New Jersey 07836. The company
year end is December&nbsp;31, 2008.
</DIV>

<DIV align="left">
<A name="102"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THE OFFERING</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Securities Being Offered
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Up to 13,630,000 shares of our
common stock held by the HCA
shareholders named in this
prospectus.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Offering Price and Plan of Distribution
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The selling shareholders named in
this prospectus will sell 13,630,000 shares of our common
stock offered under this
prospectus at an offering price of$0.50 per
share unless the offered
shares are quoted on the
Over-the-Counter Bulletin Board.
We intend to apply to the
Over-the-Counter Bulletin Board to
allow for the trading of our
common stock when we become a
reporting entity under the
Securities</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Exchange Act of 1934.
If our common stock becomes so
traded and a market for the stock
develop, the actual price of our
stock will be determined by
prevailing market prices at the
time of sale or by private
transactions negotiated by the
shareholders named in this
prospectus. The offering price
would thus be determined by market
factors and the independent
decisions of the selling
shareholders in this prospectus.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Minimum Number of Shares to be sold in
this Offering
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">None</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Securities issued and to be issued
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13,600,000 shares of our common
stock are issued and outstanding
as of the date of this prospectus.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Use of Proceeds
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">We will not receive any proceeds
from the sale of the common stock
listed in this prospectus by the
shareholders. The selling
shareholders will receive the
proceeds from any resale of our
common stock covered by the
prospectus.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<A name="103"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SUMMARY FINANCIAL INFORMATION</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">As of Period</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Balance Sheet Data</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Ended December 31, 2008</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">14,209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total Assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">14,209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total Liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">453,601</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:15px; text-indent:-15px">Stockholders&#146; Deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(439,392</TD>
    <TD nowrap>)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">For the Period from Inception</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">On February 26, 2008</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Statement of Operations Data</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">To December 31, 2008</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">635,078</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net Income (Loss)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">(740,792)</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Investment in HCA involves significant risks. The Company will not be raising any funds in this
offering. We will need to raise additional funds to meet future requirements.
</DIV>

<DIV align="left">
<A name="104"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>RISK FACTORS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">There is no assurance that our business will be profitable. An investment in our common stock
involves high degrees of risk. You should carefully consider the risks described below and the
other information in this prospectus before investing in our common stock. If any of the following
risks occur, our business operating results and financial condition could be seriously harmed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">You cannot evaluate the investment merits of our Company because we have no operating history.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We were incorporated in February&nbsp;26, 2008 and we have not started our proposed business operations
or realized any revenues, which makes it difficult to evaluate the investment merits of our
Company. We are a start-up company. We have no operating history and we do not have any business
prior to our organization. As of December&nbsp;31, 2008 we incurred total expenses of $635,078.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We may not be able to continue as a going concern if we do not obtain additional financing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Because our lack of sufficient funds and short operating history incurring only expenses, and no
revenues, our independent accountants&#146; audit report states that there is substantial doubt about
our ability to continue as a going concern. Our independent auditor in their audit report have
stated that we incurred only losses since our inception raising substantial doubt about our ability
to continue as a going concern. Therefore, our ability to continue as a going concern is highly
dependent upon obtaining additional financing for our planned operations. As of the date hereof,
all our cash has been raised from the issuance of securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We are highly dependent on our senior management. The loss of our executive officers could hinder
our ability to pursue our stated plan of operations and obtain debt or equity financing, if and
when required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We believe that our continued success depends to a significant extent upon the efforts and
abilities of our senior management and in particular, Gary Sekulski, CEO. Mr.&nbsp;Sekulski has been in
the prescription drug industry for over 35&nbsp;years. We believe that the loss of Mr.&nbsp;Sekulski&#146;s
business and management experience could hinder our ability to pursue our stated plan of operations
and obtain debt or equity financing, if and when required.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Risks Associated with this Offering</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Because we have nominal assets, we are considered a &#147;shell company&#148; and will be subject to more
stringent reporting requirements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Securities and Exchange Commission (&#147;SEC&#148;) adopted rules which defines (as defined by Rule&nbsp;405
of the Securities Act and Exchange Act Rule&nbsp;12b-2) a shell company as a registrant that has no or
nominal operations, and either (a)&nbsp;no or nominal assets; (b)&nbsp;assets consisting solely of cash and
cash equivalents; or (c)&nbsp;assets consisting of any amount of cash and cash equivalents and nominal
other assets. Our balance sheet states that we have cash as our only asset therefore, we are
defined as a shell company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our two directors, Gary Sekulski and Joseph Drucker, control approximately 92% of our outstanding
shares of common stock. The interests of our directors may not be, at all times, the same as that
of other shareholders. Since our directors are not simply passive investors but are also our
directors and officers of the company, their interests as management may, at times, be adverse to
those of passive investors. Where those conflicts exist, our shareholders will be dependent upon
our management exercising, in a manner fair to all of our shareholders, his fiduciary duties as an
officer or as a member of our board of directors. Also, management will have the ability to
significantly influence the outcome of most corporate actions requiring shareholder approval,
including the merger of Services with or into another company, the sale of all or substantially all
of our assets and amendments to our articles of incorporation. This concentration of ownership
with our directors may also have the effect of delaying, deferring or preventing a change in
control of HCA, which may be disadvantageous to minority shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If the shareholders sell a large number of shares all at once or in blocks, the market price of our
shares would most likely decline.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our common stock is presently not traded or quoted on any market or securities exchange, but should
a market develop, shares sold at a price below the current market price at which the common stock
is quoted will cause that market price to decline. Moreover, the offer or sale of a large number
of shares at any price may cause the market price to fail. The shares of common stock covered by
this prospectus represent 100% of the common shares outstanding as of the date of this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Because there is no public trading market for our common stock, you may not be able to resell your
shares.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have
very limited financial resources. As of December&nbsp;31, 2008 we had
total assets of
$14,209 consisting of cash on hand and an accumulated deficit of
($439.392). Our auditor has
issued a &#147;going concern&#148; opinion and has expressed substantial doubt about our ability to continue
as a going concern. Our continuance as a going concern is dependent on our ability to obtain
equity or debt financing and generate profitable revenues. Even if we do obtain adequate capital,
the outcome or success cannot be predicted with any certainty at this time. Our financial
statements do not include any adjustments for these uncertainties. If we cannot continue as a
viable entity, we will suspend or cease operations. If this were to occur, stockholders may lose
their entire investment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Further, our company plans to have its shares quoted on the OTC Bulletin Board. There are no
assurances that we will be successful in listing our shares. There is currently no public trading
market for our common stock. Therefore there is no central place, like a stock exchange or
electronic trading system, to resell your shares. If you do want to resell your shares, you will
have to locate a buyer and negotiate your own sale. Therefore, you may not be able to resell your
shares.
</DIV>

<DIV align="left">
<A name="105"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FORWARD-LOOKING STATEMENTS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Some of the statements under the &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Plan of Operations,&#148;
&#147;Business&#148; and elsewhere in this prospectus constitute forward-looking statements. These
statements involve known and unknown risks, uncertainties and other factors that may cause our
actual results, levels of activity, performance, or achievements to be materially different from
any future results, levels of activity, performance, or achievement expressed or implied by such
forward-looking statements. Such factors include, among other things, those listed under &#147;Risk
Factors&#148; and elsewhere in this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;should,&#148;
&#147;could,&#148; &#147;intend,&#148; &#147;expects,&#148; &#147;plan,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147; predicts,&#148;
&#147;potential,&#148; or &#147;continue&#148; or the negative of such terms or other comparable terminology.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Although we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness
of such statements. We are under no duty to update any of the forward-looking statements after the
date of this prospectus.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left">
<A name="106"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>USE OF PROCEEDS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company will not receive any proceeds from the registration of common shares in this
prospectus.
</DIV>
<DIV align="left">
<A name="107"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>DETERMINATION OF OFFERING PRICE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Offering price of our common shares by which our shareholders may sell their shares prior to the
quotation of the Company&#146;s shares on the OTC Bulletin Board (&#147;OTCBB&#148;) will be arbitrarily chosen
based on our internal assessment of what the market would support. Our founding shareholders
purchased 13,000,000 of our common shares at a price of $0.0001 per share on March&nbsp;10, 2008. The
offering price of our shares are substantially higher than the price paid by our founding
shareholders, and exceeds the per share value of our net tangible assets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">You may also suffer additional dilution in the future from the sale of additional shares of common
stock or other securities, if the need for additional financing forces HCA to make such sales.
Investors should be aware of the risk of judging the real or potential future market value, if any
of our common stock by comparison to the offering price.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">There is no established public market for the shares of common stock being registered. As a
result, the offering price and other terms and conditions relative to the shares of common stock
offered hereby have been arbitrarily determined by us and do not necessarily bear any relationship
to assets, earnings, book value or any other objective criteria of value. In addition, no
investment banker, appraiser or other independent, third party has been consulted concerning the
offering price for the shares or the fairness of the price used for the shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We intend to apply to the OTCBB to allow the quotation of our common stock upon HCA becoming a
reporting entity under the Securities Exchange Act of 1934. We intend to file this S-1
registration statement under the Exchange Act with the effectiveness of the registration statement
of which this prospectus forms a part. If our common stock becomes as quoted and a market for the
stock develops, the actual price of stock will be determined by prevailing market prices at the
time of sale of by private transactions negotiated by the selling shareholders. The offering price
would thus be determined by market factors and the independent decisions of the selling
shareholders.
</DIV>
<DIV align="left">
<A name="108"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>DILUTION</B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The common stock to be sold by the selling shareholders is common stock that is currently issued
and outstanding. Accordingly, there will be no dilution to our existing shareholders.
</DIV>
<DIV align="left">
<A name="109"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SELLING SECURITY HOLDERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The selling shareholders named in this prospectus are offering 13,630,000 share of our common stock
acquired by the selling shareholders from HCA in offerings that were exempt from registration.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The selling shareholders, three founding shareholders, acquired 13,000,000 shares of
our common stock from us at a price of $0.0001 per share that was exempt from registration
on March&nbsp;10, 2008.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Three selling shareholders acquired 65,000 shares of HCA common stock from a Form&nbsp;D
Reg-504 Private Placement Memorandum at $0.50 per share.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>First Time II LLC purchased 400,000 shares under a Stock Purchase Agreement dated
August&nbsp;28, 2008 for a purchase price of $0.50 per share.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The term &#147;selling shareholders&#148; includes donees, pledges, transferees or other
successors-in-interest selling shares received after the date of this prospectus from a selling
shareholder as a gift, pledge or other non-sale related transfer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Based on information provided to us by the selling shareholders, the following table provides
information as of December&nbsp;31, 2008, regarding the number of shares of our common stock held by
each of the selling shareholders as of the date hereof, including: (1)&nbsp;the total number of shares
that are to be offered by each; (2)&nbsp;the percentage owned by each prior to the offering; (3)&nbsp;the
percentage owned by each upon completion of the offering; and (4)&nbsp;the identity of the beneficial
holder of any entity that owns the shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as disclosed in the table below, to the best knowledge of management of the Company, the
named party beneficially owns and has sole voting and investment power over all shares or rights to
these shares. The numbers in the table assume that none of the selling shareholders sells shares
of common stock not being offered in this prospectus or purchases additional shares of common
stock, and assumes that all shares offered are sold.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as disclosed below, none of the selling shareholders
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>has had a material relationship with us or any of our affiliates other than as
a security holder at any time within the past three years; or *</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>has ever been one of our officers or directors.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Except for # 1, 2 and 3 who are officers and directors</TD>
</TR>

</TABLE>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"></TD>
</TR>

<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Shares Beneficially Owned</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Total Shares</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Shares Beneficially Owned</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">Name and Address of</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">Prior to the Offering</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Offered by this</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">After the Offering</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Selling Shareholders</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Percent</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Prospectus <sup>(1)</sup></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Percent</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD align="left" valign="top">1</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">Gary Sekulski</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9,500,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9,500,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">56 Kevin Drive<br>
Flanders, NJ 07838</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">The Joseph Drucker</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3,000,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3,000,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">1995 Trust<br>
c/o Thomas Fortin Trustee<br>
165 East 66 Street<br>
New York, NY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD align="left" valign="top">3</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">Jan Goldberg</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">500,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">500,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">Matilda Bruno</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">50,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">50,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD align="left" valign="top">5</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">Steve Monetti</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20.000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20.000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">6</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">Colonial Consulting Group LLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">60,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">60,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD align="left" valign="top">7</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">Buy and Sell Pharmacy.com</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">25,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">25,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">8</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">Scott M. Cutler</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD align="left" valign="top">9</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">Joann R. DeSheplo</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">Wayne Miller</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD align="left" valign="top">11</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">Kathleen Muhlmeister</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">25,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">25,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">12</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">First Time II LLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">400,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">400,000</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">0.0</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="110"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PLAN OF DISTRIBUTION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Summary

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have agreed to register for public resale our common shares, which have been issued to the
selling shareholders. This offering will terminate on the earlier of (i)&nbsp;the date on which the
shares may be resold by the selling stockholders without registration and without regard to any
volume limitations by reason of Rule&nbsp;144 under the Securities Act or any other rule of similar
effect or (ii)&nbsp;all of the shares have been sold pursuant to this prospectus of Rule&nbsp;144 under the
Securities Act or any other rule of similar effect. The selling shareholders will receive all of
the net proceeds from their sales. Prior to having the shares quoted on OTCBB, the selling
shareholders may, from time to time, sell all or a portion of the shares of common stock of our
Company, which they own at $0.50 per share. After the shares of the Company are quoted for trading
on the OTCBB, the selling shareholders may sell their shares at the then market prices on the OTCBB
or privately negotiated prices, which may be less than or greater than $0.50 per share. Presently,
the selling shareholders cannot sell their common stock of our company except in accordance with
new Rule&nbsp;144 under the Securities Act because we are defined as a &#147;shell company.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The selling shareholders may sell their shares of common stock of our company directly to
purchasers or may use brokers, dealers, underwriters or agents to sell such Shares. Brokers or
dealers may receive commissions, discounts or concessions from a selling shareholder or, if any
such broker or dealer acts as agent for the purchaser of such shares, from a purchaser in amounts
to be negotiated. Such compensation may, but is not expected to, exceed that which is customary
for the types of transactions involved.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The selling shareholders and any brokers, dealers or agents that participate with the selling
shareholders in sales of their shares or common stock of our Company may be deemed to be
&#147;underwriters&#146; within the meaning of the Securities Act of 1933 in connection with such sales. In
such event, any commissions received by such brokers, dealers or agents and any profit on the
resale of such shares purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act of 1933.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We are required to pay all fees and expenses incident to the registration of our shares of common
stock offered hereby other than broker or dealer discounts and commissions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The officers and directors of HCA have agreed to sell only shares as allowed by the volume
limitations under Rule&nbsp;144 for the first year that company stock is traded on the OTCBB.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="111"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SELLING SHAREHOLDER&#146;S &#147;UNDERWRITER&#148; STATUS: PROSPECTUS DELIVERY REQUIREMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Shareholders of the Company who resell their securities pursuant to this prospectus may be deemed
to be statutory &#147;underwriters&#148; (as defined in Securities Act of 1933 Section&nbsp;2(11)) and &#147;engaged in
a public distribution.&#148; Accordingly, HCA intends to deliver a prospectus to each shareholder.
Each selling shareholder should review it carefully and deliver it to any broker or dealer engaged
to sell stock or to any buyer in a direct sale. Selling shareholders and certain brokers and
dealers are required to deliver a prospectus 48 hours prior to confirming sales. Additional copies
of the prospectus may be printed by accessing it on the SEC website at http:\www.sec.gov, or it may
be obtained by writing or calling Healthcare Corporation of America, 36 Kevin Drive, Flanders, New
Jersey 07836, telephone 973 796 4216. See &#147;Selling shareholders&#148; above for information as to the
largest shareholders, the amounts owned, and any relationships with HCA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Suggested Selling Shareholder&#146;s Underwriting Compliance Procedures
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as indicated under &#147;Selling Shareholders&#148; none of the shareholders is known to HCA to be a
broker-dealer or affiliates of broker-dealers or to have any experience in the distribution of
securities or to have any material relationships with HCA. HCA is not aware of any intent by a
shareholder to engage in passive market making transactions as permitted by Rule&nbsp;10b-6A under the
Securities Exchange Act of 1934 or in stabilization or other transactions affecting the market
price. We are not aware of any intent by our officers, directors or principal shareholders to
purchase shares from selling shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It is suggested to selling shareholders that, to avoid technical violations of underwriting
regulations, they should observe the prospectus delivery requirement described herein and also
consult with their legal counsel. These suggestions do not constitute legal advice or any
representation or warranty that these are necessary or sufficient to comply with or avoid
enforcement action (civil or criminal) for alleged violations of any type of law. Shareholders
engaging in any direct or indirect transactions of any nature as to any of HCA&#146;s securities do so
at their own risk and expense. All sales should be conducted through brokers or dealers, who
should be given a copy of the prospectus and advised of the SEC and NASD position that such sales
may be deemed to be part of a &#147;public distribution&#148; by statutory &#147;underwriters&#148; (selling
shareholders). No purchases of shares or other transactions having the purpose or effect of
affecting the price should be engaged in my or on behalf of shareholders before or after the sale.
HCA&#146;s public reporting status should be brought to the brokers&#146; or dealers&#146; attention. Updated
information about HCA will be in the reports to the SEC at
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">http:\www.sec.gov. See &#147;Available Information&#148; near the end of the prospectus for further details
on how to obtain copies of such reports.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Although isolated resales often are exempt from state &#147;blue sky&#148; securities regulation and
registration requirements and the reporting company status of an issuer broadens the availability
of resale exemptions, selling shareholders should be cautious in view of their &#147;underwriter&#148; status
in the eyes of the SEC and NASD. They are urged to consult qualified local securities counsel.
HCA is not undertaking, and it will be the selling shareholders&#146; responsibility, to file any
necessary state exemption, qualification, or registration statements or notices (such as Form U-1)
and offering documents (such as this prospectus) if needed for resales in a particular state.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The selling shareholders may offer their shares of common stock at various times in one or more of
the following transactions:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the over-the-counter market;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In private transactions other than in the over-the-counter market;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In connection with short sales of our shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By pledge to secure debts and other obligations; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In a combination of any of the above transactions.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The selling shareholders may sell their shares at market prices prevailing at the time of the sale,
at prices related to such prevailing market prices, at negotiated prices or fixed prices. Until
the shares of the Company are quoted for trading on the OTCBB, the selling shareholders will sell
their shares at a price of $0.50 per share. After the shares of the Company are quoted for trading
on the OTCBB, the selling shareholders may sell their shares at the then market price on the OTCBB
or privately negotiated prices, which may be less than or greater than $0.50 per share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The selling shareholders may use brokers or dealers to sell their shares. Sales through brokers of
dealers may involve one or more of the following;
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Block trades in which the broker or dealer so engaged will attempt to sell the selling
shareholder&#146;s shares as agent but may position and resell a portion of the block as
principal to facilitate the transaction;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Purchases by a broker or dealer as principal and resale by such broker or dealer for its
own account pursuant to this prospectus; or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Ordinary brokerage transactions and transactions in which the broker solicits
purchasers.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If a broker or dealer is engaged by a selling shareholder, such broker or dealer may either receive
discounts or commissions from the selling shareholders, or they will receive commissions from
purchasers of shares for whom they acted as agents. Affiliates of one or more of the selling
shareholders may act as principals or agents in connection with the offer or sale of shares by
selling shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Selling shareholders also may resell all or a portion of the shares in open market transactions in
reliance upon Rule&nbsp;144 under the Securities Act of 1933, as amended, provided that they meet the
criteria and conform to the requirements of that Rule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Selling shareholders have been advised that during the time each is engaged in distribution of the
securities covered by this prospectus, to the extent applicable, each must comply with Regulation&nbsp;M
under the Securities Exchange Act of 1934, as amended, and pursuant to such Regulation:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Shall not engage in any stabilization activity in connection with our securities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Shall furnish each broker through which securities covered by this prospectus may be
offered the number of copies of this prospectus which are required by each broker; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Shall not bid for or purchase any of our securities or attempt to induce any person to
purchase any of our securities other than as permitted under the Securities Exchange Act of
1934, as amended.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The selling shareholders and any brokers, dealers or agents that participate with the selling
shareholder in sales of the shares may be deemed to be underwriters within the meaning of the
Securities Act in connection with such sales and subject to any liabilities under such Act. Any
commissions received by such brokers, dealers or agents and any profit on the resale of the shares
purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act.
</DIV>
<DIV align="left">
<A name="112"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>LEGAL PROCEEDINGS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We are not currently a party to, nor are any of our property currently the subject of, any pending
legal proceeding. None of our directors, officers or affiliates is involved in a proceeding
adverse to our business or has a material interest adverse to our business.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Our agent for service of process is Joseph Drucker, Attorney at Law, 43 Sawgrass Street, Jackson,
New Jersey 08520.
</DIV>
<DIV align="left">
<A name="113"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following table sets forth the directors and executive officers of our company, their ages,
term served and all officers and positions with our Company. Pursuant to our bylaws, our directors
are elected at our annual meeting of stockholders and each director holds office until the
successor is elected and qualified. Officers are appointed by our Board of Directors and hold
office until an officer&#146;s successor has been duly appointed and qualified unless an officer sooner
dies, resigns or is removed by the Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">There are no arrangements or understandings regarding the length of time a director of our company
is to serve in such a capacity.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Name</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="1" style="border-bottom: 1px solid #000000">Age</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Position</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Gary Sekulski
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="CENTER" valign="top">61</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director, President and CEO</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Joseph Drucker
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="CENTER" valign="top">87</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director, Secretary, Corporate Counsel</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jan Goldberg
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="CENTER" valign="top">57</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Executive Vice President, Administration</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Set forth below is a brief description of the background and business experience of our current
executive officers and directors:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Gary J. Sekulski &#150; CEO, President and Director</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Sekulski is an experienced executive with a primary focus on business development and the
development of products and services to effectively address operational and marketing challenges in
the healthcare and prescription drug market sectors. Mr.&nbsp;Sekulski was a Founder and President of
Broadreach Medical Resources where he created a new more cost effective business model for
administrating prescription drug programs using transparency and full disclosure business
practices. He was President of the Gladstone Consulting Group, a healthcare product development,
medical underwriting and project management company that developed innovative products in chronic
illness management, prescription drugs and dental. Over the years, Mr.&nbsp;Sekulski has held various
executive positions with organizations such as Executive Vice President at Summit Health
Administrators, an organization that processed the professional claims for HIP of New York
servicing HIP&#146;s 1.2&nbsp;million members, and Senior Vice President of Product Development at Medco
Containment Services (now Medco Health Solutions), where he was instrumental in developing mail
service plans, integrated walk-in card/mail service plans, managed care pharmacy networks,
formulary/ rebate programs and the marketing strategies to implement these programs. Prior to
this, Mr.&nbsp;Sekulski had been the National Director of Metropolitan Life Insurance Company&#146;s provider
network programs including prescription drugs
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(GM, Goodyear, GE), vision (created Bell Company and AT&#038;T original program) and dental (formulated
first national network). In this capacity, claims operations with over 750 employees reported to
Mr.&nbsp;Sekulski. While at Metropolitan, Mr.&nbsp;Sekulski also supervised Metropolitan&#146;s Internal Medical
Underwriting Division. Mr.&nbsp;Sekulski has served on the 1985 General Motors/UAW Benefits Cost
Containment Task Force; the Medicare Catastrophic Prescription Drug Act Committee; Chair of the
HIAA Pharmaceutical Relations Committee; Chair of the By-laws Committee-National Council of
Prescription Drug Programs. He has also been a member of the Self-Insurance Institute of America,
and the National Association of Chain Drug Stores. Mr.&nbsp;Sekulski is a graduate of Stony Brook
University.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Jan Goldberg-Executive Vice President -Administration</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Goldberg has a proven record of improving operations and unit performance while reducing costs
in the challenging health care environment. He has managed complex multiple sites and large
operations, negotiated mergers and acquisitions, labor contracts and business contracts. Mr.
Goldberg&#146;s diverse career has included Senior Vice President of Facility Operations for Integrated
Medical LLC, a medical and Real Estate Management Company; Principle, Founder and Executive Vice
President of Modern Medical Modalities Corporation, a multi state diagnostic imaging company;
Founder and President of CSB Billing and Management Inc., a physician billing company located in
Florida. He has also served as Director of Operations for Advacare, Inc. a national billing and
Management Company and as New Jersey Director of Operations for Sonix Medical Resources. Early in
his career he has served in the finance departments of Booth Memorial Medical Center and Staten
Island University Medical Center. He started his career with Blue Cross/ Blue Shield of Greater New
York. Mr.&nbsp;Goldberg is a graduate of Pace University.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Joseph Drucker-Corporate Counsel, Secretary and Director</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Drucker, Esq., manages HCA&#146;s Legal Department and Legal affairs which will include overseeing
HCA&#146;s filings with the Securities and Exchange Commission. Mr.&nbsp;Drucker has had a distinguished
career from 1946 to date serving as a Director and Officer of both Private and Public Corporations.
From 1983 to 1997, Mr.&nbsp;Drucker served as Co-Chairman, Secretary and General Counsel of a small cap
public Company. Mr.&nbsp;Drucker has been in the private practice of law since 1973. He was a partner
in the law firm of Himmelman, Hurley, Drucker and Himmelman. As an attorney, Mr.&nbsp;Drucker limits
his practice to corporate law and specializes in the formation of business plans, Private Placement
Memoranda and the filing of registration statements with the Securities and Exchange Commission to
authorize the sale of Company&#146;s securities to public investors and reverse mergers. Mr.&nbsp;Drucker&#146;s
diverse career also included being a managing partner of the accounting firm of Reimer, Drucker,
Biegeleisen and Standard located in Freehold, New Jersey. Mr.&nbsp;Drucker Attended Columbia University
and received a B.S. Degree in Business and Accounting from Long Island University and a Juris
Doctorate Degree from Brooklyn Law School.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Summary Annual Compensation Table</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
     <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Compensation-</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">October 1, 2008</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000">($) Number of shares</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Name and Principal Position</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">($) Salary</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">($) Bonus</TD>
    <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Underlying Options (#)</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Gary Sekulski, CEO</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">360,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Joseph Drucker, Secy</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">120,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Jan Goldberg, Exec VP</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">180,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">See financial statements Note 3, Executive Compensation (accrued salaries).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Director Compensation Table
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Fees Earned or</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stock Awards of</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Paid in Cash</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Options</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">All other Compensation</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Name</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">($)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">($)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">($)</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Gary Sekulski</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Joseph Drucker</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NONE</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Note: Board of Directors will determine if bonus payments will be made at end of fiscal year based
on financial position. Board of Directors may also determine if fees will be paid to Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We do not presently have a stock option plan but intend to develop an incentive based stock option
plan for our officers and directors in the future and may reserve a percentage of our outstanding
shares of common stock for that purpose.
</DIV>
<DIV align="left">
<A name="114"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>COMMITTEES OF THE BOARD OF DIRECTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The functions of the audit committee are currently carried out by our Board of Directors. We do
not have a financial expert on our Board. Our Board has determined that we do not need such an
expert. The cost of hiring a financial expert to act as a director of HCA and to be a member of
the audit committee or otherwise perform audit committee functions outweighs the benefits of joromg
a financial expert on the audit committee. We do not have a compensation committee, nominating
committee, an executive committee on our board of directors, stock plan committee or any other
committees.
</DIV>
<DIV align="left">
<A name="115"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">None of our directors, executive officers, promoters or control persons has been involved in any of
the following events during the past five years:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any bankruptcy petition filed by or against any business of which such person was a
general partner or executive officer either at the time of the bankruptcy or within two
years prior to that time;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any conviction in a criminal proceeding or being subject to a pending criminal
proceeding (excluding traffic violations and other minor offences);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>being subject to any order, judgment or decree, not subsequently reversed, suspended or
vacated of any court of competent jurisdiction, permanently or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type
of business, securities or banking activities; or</TD>
</TR>

<tr style="font-size: 6pt">
    <TD>&nbsp;</TD>
</tr>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>found by a court of competent jurisdiction (in a civil action ), the Commission or the
Commodity Futures Trading Commission to have violated a federal or state securities or
commodities law, and the judgment has not been reversed, suspended, or vacated.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left">
<A name="116"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following table sets forth certain information as of December&nbsp;31, 2008, with respect to the
beneficial ownership of our company&#146;s common stock with respect to each named director and
executive officer of our Company, each person known to our company to be the beneficial owner of
more than five percent (5%) of said securities, and all directors and executive officers of our
Company as a group. Unless otherwise indicated, the address for each listed person is c/o
Healthcare Corporation of America, 36 Kevin Drive, Flanders, New Jersey 07836.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Amount and Nature</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">of Beneficial</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Percentage</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Name and Address</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Title of Class</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Ownership</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">of Class</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Gary Sekulski</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Common</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69.9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">President, CEO and Director</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Joseph Drucker</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Common</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22.0</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Secretary and Director</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">JanGoldberg</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Common</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Vice President administration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>The percentage of class is based on 13,630,000 shares of common stock issued and outstanding
as of the date hereof.</TD>
</TR>

</TABLE>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The persons named above have full voting and investment power with respect to the shares indicated.
Under the rules of the Securities and Exchange Commission, a person (or group of persons) is
deemed to be a &#147;beneficial owner&#148; of a security if he or she, directly or indirectly, has or shares
the power to vote or to direct the voting of such security, or the power to dispose of or to direct
the disposition of such security. Accordingly, more than one person may be deemed to be a
beneficial owner of the same security. A person is also deemed to be a beneficial owner of any
security which that
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">person has the right to acquire within 60&nbsp;days, such as options or warrants to purchase our common
stock.
</DIV>
<DIV align="left">
<A name="117"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>DESCRIPTION OF CAPITAL STOCK</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The shares registered pursuant to this registration statement are shares of common stock, all of
the same class and entitled to the same rights and privileges as all other shares of common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Common Stock</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HCA is presently authorized to issue 25,000,000 shares of common stock, no par value per share. As
of the date hereof, there were 13,630,000 shares of our common stock issued and outstanding, held
by 12 stockholders of record.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Our common stock is entitled to one vote per share on all matters submitted to a vote of the
stockholders, including the election of directors. Except as otherwise required by law or provided
in any resolution adopted by our board of directors with respect to any series of preferred stock,
the holders of our common stock will possess all voting power. Generally, all matters to be voted
on by stockholders must be approved by a majority (or in the case of selection of directors, by a
plurality) of the votes entitled to be cast by all shares of our common stock that are present in
person or represented by proxy, subject to any voting rights granted to holders of any preferred
stock. Holders of our common stock representing ten-percent (10%) of our capital stock issued,
outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a
quorum at any meeting of our stockholders. A vote by the holders of a majority of our outstanding
shares is required to effectuate certain fundamental corporate changes such as liquidation, merger
or an amendment to our Articles of Incorporation. Our Articles of Incorporation do not provide for
cumulative voting in the election of directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Subject to any preferential rights of any outstanding series of preferred stock created by our
board of directors from time to time, the holders of shares of our common stock will be entitled to
such cash dividends as may be declared from time to time by our board of directors from funds
available therefore. See &#147;Dividend Policy.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Subject to any preferential rights of any outstanding series of preferred stock created from time
to time by our board directors, upon liquidation, dissolution or winding up of HCA, the holders of
shares of our common stock will be entitled to receive pro rata all assets of HCA available for
distribution to such holders.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In the event of any merger or consolidation of our company with or into another company in
connection with which shares of our common stock are converted into or exchangeable for shares of
stock, other securities or property (including cash), all holders of our common stock will be
entitled to receive the same kind and amount of shares of stock and other securities and property
(including cash).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Holders of our common stock have no pre-emptive rights, no conversion rights and there are no
redemption provisions applicable to our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Preferred Stock</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As of the date hereof, HCA has no preferred stock authorized or issued.
</DIV>
<DIV align="left">
<A name="118"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>DIVIDEND POLICY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have never declared or paid any cash dividends on our common stock. We currently intend to
retain future earnings, if any, to finance the expansion of our business. As a result, we do not
anticipate paying any cash dividends in the foreseeable future.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Share Purchase Warrants</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have not issued and do not have outstanding any warrants to purchase shares of our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Options</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have not issued and do not have outstanding any options to purchase shares of our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Convertible Securities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have not issued and do not have outstanding any convertible into shares of our common stock or
any rights convertible or exchangeable into shares of our common stock.
</DIV>
<DIV align="left">
<A name="119"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>LEGAL MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Joseph Drucker has provided an opinion of the validity of our common stock offered by the Selling
Shareholders.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Experts
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Moore Associates, (&#148;Chartered Accountants&#148;), our independent registered public accounting firm, has
audited our financial statements included in this prospectus and registration statement to the
extent and for the period set forth in their audit report. Moore Associates has presented their
report with respect to our audited financial statements. The report of Moore Associates is
included in reliance upon their authority as experts in accounting and auditing.
</DIV>
<DIV align="left">
<A name="120"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">There have not been any changes in or disagreements with our accountants on accounting and
financial disclosure or any other matter.
</DIV>
<DIV align="left">
<A name="121"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>No Public Market for Common Stock</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">There is presently no public market for our common stock. We anticipate making an application for
trading of our common stock on the OTCBB upon the effectiveness of this registration statement of
which the prospectus forms a part. We are qualifying for resale up to 13,630,000 common shares
pursuant to this registration statement. However, we can provide no assurance that our shares will
be traded on the bulletin board or, if traded, that a public market will materialize.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>New Rule&nbsp;144</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HCA is presently a &#147;shell company&#148; as defined under rule 405 of the Securities Act and Rule&nbsp;12b-2
of the Exchange Act. Effective February&nbsp;15, 2008, the SEC amended Rule&nbsp;144 of the Securities Act
of 1933, which do not allow shareholders to rely on Rule&nbsp;144 for the resale of securities of a
shell company. Shareholders may only rely on new Rule&nbsp;144 if HCA ceases to be a shell company and
only if all of the following conditions are met: the issuer has ceased to be a shell company; the
issuer is subject to the reporting requirements of the Exchange Act; the issuer has filed all
Exchange Act reports required for the past 12&nbsp;months; and at least one year has elapsed from the
time that the issuer filed current Form&nbsp;10 information on Form 8-K changing the status to a
non-shell company.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If HCA is
defined as not a &#147;shell company,&#148; a total of 13,630,000 shares of our restricted common
stock will be available for resale to the public, in accordance with the volume and trading
limitations of new Rule&nbsp;144. Also pursuant to the amended provision of Rule&nbsp;144, following the
six-month holding period but before one year after their acquisition of the securities, a person
who is not an affiliate and has not been an affiliate for at least three months prior to the sale,
will be able to make unlimited public resales under Rule&nbsp;144 except that the current public
information requirement will still apply. After the one-year holding period, such non-affiliates
may make unlimited public resales under rule 144 and need not comply with any other rule 144
requirements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The one year and six month holding periods described above do not begin to run until the full
purchase price or other consideration is paid by the person acquiring the shares from the issuer or
an affiliate. However, we are a &#147;shell company&#148; and shareholders holding restricted stock cannot
rely on Rule&nbsp;144 to resell their restricted shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Penny Stock Regulation</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Our shares will have to comply with the Penny Stock Reform Act of 1990, which may potentially
decrease your ability to easily transfer our shares. Broker-dealer practices in connection with
transactions in &#147;penny Stocks&#148; are regulated. Penny stocks generally are equity securities with a
price of less than $5.00. the penny stock rules require a broker-dealer, prior to a transaction in
a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure
document that provides information about penny stocks and the risks in the penny stock market. The
broker-dealer also must provide the customer with current bid and other quotations for the penny
stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly
account statements showing the market value of each penny stock held in the customer&#146;s account. In
addition, the penny stock rules generally require that prior to a transaction in a penny stock, the
broker-dealer make a special written determination that the penny stock is a suitable investment
for the purchaser and receive the purchaser&#146;s written agreement to the transaction. These
disclosure requirements may have the effect of reducing the level of trading activity in the
secondary market for a stock that has to comply with the penny stock rules. As our shares
immediately following this offering will likely have to comply with such penny stock rules,
investors in this offering will in all likelihood find it more difficult to sell their securities.
</DIV>
<DIV align="left">
<A name="122"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>EXPERTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The financial statements included in this prospectus have been audited by Moore &#038; Associates,
Chartered Public Accountants. Reference is made to the auditor&#146;s report. These financial
statements are furnished in reliance upon the auditor&#146;s report.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="123"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>INDEMNIFICATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">New Jersey corporate law provides that a corporation may indemnify any person who was or is a
party, or is threatened to be made a party, to any threatened, pending or completed action, suit or
proceeding whether civil, criminal administrative or investigative, except an action by or in the
right of the corporation, by reason of the fact that he is or was a director, officer, employee or
agent of the corporation, or is or was serving at the request of the corporation as director,
officer, employee or agent of another corporation, partnership, joint venture, trust of other
enterprise, against expenses, including attorneys&#146; fees, judgments, fines and amounts paid in
settlement actually and reasonably incurred by him in connection with the action, suit or
proceeding if he acted in good faith and in a manner which he reasonable believed to be in or not
opposed to the best interests of the corporation, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe his conduct was unlawful.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">New Jersey corporate law also provides that, to the extent that a director, officer, employee or
agent of a corporation has been successful on the merits or otherwise in defense of any action,
suit or proceeding, or in defense of any claim, issue or matter therein, the corporation shall
indemnify him against expenses, including attorneys&#146; fees, actually and reasonably incurred by him
in connection with the defense.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Our Articles of Incorporation and By-Laws limit the liability of our directors, officers, agents,
fiduciaries and employees to the fullest extent permitted by the New Jersey Revised Statutes.
Specifically, directors of the company will not be personally liable to the Company or any of its
shareholders for monetary damages for breach of fiduciary duty as directors, except liability for:
(i)&nbsp;any breach of the director&#146;s duty of loyalty to the corporation or its shareholders; (ii)&nbsp;acts
or omissions not in good faith or which involve intentional misconduct or a knowing violation of
law; (iii)&nbsp;voting for or assenting to a distribution in violation of New Jersey law; or (iv)&nbsp;any
transaction from which the director directly or indirectly derives an improper personal benefit.
Our governing documents therefore protect officers, directors, agents, fiduciaries, and employees
to the fullest extent permissible under New Jersey law.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>DISCLOSURES OF COMMISSION&#146;S POSITION ON INDEMNIFICATION<BR>
OF SECURITIES ACT LIABILITIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have been advised that in the opinion of the Securities and Exchange Commission indemnification
for liabilities arising under the Securities Act of 1933, as amended, is against public policy as
expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities is asserted by one of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">our directors, officers, or
controlling persons in connection with the securities being registered, we will either rely upon
the opinion of counsel as to whether or not to pay indemnification, or submit the matter to a court
of appropriate jurisdiction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Dividends</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">No dividends have been declared on the common shares as of the date hereof and the Company has no
plans to declare dividends in the near future.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Disclosures of Commission Position on Indemnification for Securities Act Liabilities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
directors, officers and controlling persons of the registrant pursuant to the foregoing provisions,
or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In the event that a claim for indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or controlling person of the
registrant in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court or appropriate jurisdiction the question whether such indemnification
bi it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issues.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The foregoing right of indemnification shall not be deemed exclusive of any rights to which any
officer or director or employee may be entitled apart from the provisions of this section.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The amount of indemnity to which any officer or any director may be entitled shall be fixed by the
Board of Directors, except that in any case where there is not disinterested majority of the Board
available, the amount shall be fixed by arbitration pursuant to the then existing rules of the
American Arbitration Association.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Transactions with Related Persons</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On March&nbsp;10, 2008, we issued 13,000,000 shares of our common stock to Gary Sekulski, Joseph Drucker
and Jan Goldberg, our directors and officers, at $.0001 per share and aggregate proceeds of $1300.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Reports to Security Holders</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We intend to furnish our stockholders annual reports containing audited financial statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The financial statements included in this prospectus have been audited by Moore &#038; Associates,
Chartered Accountants. Reference is made to the auditor&#146;s report. These financial statements are
furnished in reliance upon the auditor&#146;s report.
</DIV>
<DIV align="left">
<A name="124"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>AVAILABLE INFORMATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have filed with the SEC a registration statement on Form S-1 to cover the securities to be sold
hereunder. This prospectus forms a part of that registration statement, and the registration
statement also includes certain exhibits. This prospectus therefore does not contain all of the
information set forth in the registration statement and exhibits to the registration statement.
For further information with respect to our company and the shares of common stock to be sold in
this offering, reference is made to the registration statement, including the exhibits to the
registration statement. Copies of the registration statement, including the exhibits to the
registration statement, may be examined without charge ad the public reference room of the SEC, 100
F Street, N.W., Room&nbsp;1580, Washington, DC 20549. Information about the operation of the public
reference room may be obtained by calling the SEC at 1-800-SEC-0330. Copies of all or a portion of
the registration statement may be obtained from the public reference room of the SEC upon payment
of prescribed fees. Our SEC filings, including our registration statement, are also available to
you on the SEC&#146;s website at <U>www.sec.gov</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As a result of this offering, we will become subject to the informational and reporting
requirements of the Securities Exchange Act, and will file periodic reports, proxy statements and
will make available to our stockholders annual reports containing audited financial information for
each year and quarterly reports for the first three quarters of each fiscal year containing
unaudited interim financial information.
</DIV>
<DIV align="left">
<A name="125"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>BUSINESS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>INTRODUCTION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>GENERAL</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Healthcare Corporation of America</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any estimates and projections contained herein have been prepared by management of the company and
involve significant elements of subjective judgment and analysis.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="126"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>EXECUTIVE SUMMARY</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Healthcare Corporation of America</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Background</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The pharmaceutical market sector is the most profitable of all U.S. industries based on revenue,
equity and assets according to Fortune Magazine. Within this sector, the fastest growing and most
profitable component of the medication dispensing process is the &#147;Closed Door Pharmacy&#148; (a pharmacy
that does not service the general public). At the present time, Closed Door Pharmacies include Long
Term Care (nursing homes and assisted living facilities) Mail Order, Specialty Pharmacy, and
Central Fill Pharmacy (funded prescription drug programs).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Corporate Organization</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HCA is a
New Jersey Corporation that was formed February&nbsp;26, 2008. At the present time, HCA is a
Product Development and Marketing Company that has developed a new business model that will reduce
and control pharmacy costs for non-profit organizations through a product offering that utilizes
the Closed Door Pharmacy concept in a new and unique way. For its pharmacy ventures, HCA has
formed, Prescription Corporation of America (PCA), a wholly owned subsidiary. In order to provide
dispensing pharmacy services, PCA has entered into participating pharmacy agreements with Kings
Pharmacy, Newark, New Jersey, Jacobs Pharmacy, Paterson, New Jersey and Fountain Hill Pharmacy in
Bethlehem, Pennsylvania. HCA plans to add pharmacies to service clients in new geographic locations
as the demand for its product grows and to open HCA&#146;s own pharmacy in the future.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HCA has also entered into discussions with Standard Security Life Insurance to form a reinsurance
underwriting facility (a planned HCA subsidiary for the First Quarter 2009) in order to guarantee
the lower program costs achieved by PCA programs to plan sponsors through an Aggregate Stop Loss
Policy. In the future, HCA plans to add a Pharmacy Benefit Manager (PBM)&nbsp;subsidiary which will
service prescription drug programs, thereby, complementing HCA&#146;s two other subsidiaries and which
will add a third source of revenue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As part of its business strategy, HCA plans to become a public company. Currently, HCA is seeking
up to $1&nbsp;million in funding through a Private Placement Memorandum at $.50 per share to accelerate
its growth rate. HCA is a non-trading Company with 25&nbsp;million authorized shares of common stock.
Our intention is to file this S-1
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Registration, through a market maker file a 15c211 and become a public company trading on the
OTCBB.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Operations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">PCA&#146;s pharmacies house both Unit Dose (packaging of medications by Bingo Punch Cards, Unit Dose
Boxes or PAC Med Pouches) and Vial (packaging of medications into patient specific containers) Base
dispensing capabilities in one Closed Door Pharmacy. This gives PCA access to the long term care
and funded prescription drug program market sectors as a Long Term Care Pharmacy, Mail Order
Pharmacy and Central Fill Pharmacy. While each of these pharmacies service different end
recipients, there is commonality in staff, particularly among pharmacists, administrative functions
and purchasing practices. As part of the plan, HCA will centralize corporate staff, sales and
marketing, pharmaceutical purchasing and redundant administrative functions in one location. It is
anticipated that this structure will add margin because of the improved overall cost effectiveness
of the Company and due to the improvement in purchasing practices of medications with the
consolidation of volume.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Marketing Strategy</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With this multiple pharmacy capability, HCA is focusing on the non-profit market sector which
includes school districts, charitable organizations, hospitals, colleges, non-profit long term care
facilities and universities. HCA has worked closely with the Federal Trade Commission and has
received several favorable rulings from governmental agencies that permit PCA to improve purchasing
practices and pricing for these non-profit entities. This has become a significant competitive
advantage for HCA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HCA has also been approached by several Home Health Care Agencies to have PCA could formulate a
solution to the administration of medication to home patients being serviced by these agencies.
Currently, to comply with laws, Nurses must transfer medications from vials obtained at the
patient&#146;s pharmacy to daily dose 30&nbsp;day bingo cards so that care givers can distribute medications
to patients. In response to this demand, PCA has formulated a new pharmacy product for this market
sector which solves the medication administration problems for home care agencies at a reduce cost
to the home care patients these agencies service by using unit dose pouch packaging with direct
home delivery.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In order to promote the fastest distribution of product in the market, HCA has decided to
compliment its internal sales efforts and has contracted with or is in the process of contracting
with several major sales distribution systems that present multiple immediate business
opportunities. These organizations include the Colonial
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Consulting Group; Willis HRH, a top 10 national insurance broker employee benefit consultant;
independent sales agents, John Wohtowicz and AXA Financial Group.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Current Status</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">PCA launched its Non-Profit Pharmacy Program in the fall of 2008. PCA is implementing its first
group of clients effective Second Quarter&nbsp;2009. These include School Districts in Fort Lee, Phillipsburg, and
Toms River. In addition, PCA is adding the Fort Lee Senior Center. This encompasses approximately 10,000 family units (a family unit is the
combination of employee, employee plus spouse, employee plus children
and families)*. PCA also has a contractual commitment** from to place 10,000 family units on the non-profit program by
July&nbsp;2009. In addition, PCA is in active discussions with Bergen County Schools, Edison,
Woodbridge, Jackson, Berkley and Manchester. PCA is also
directly pursuing Englewood, Passaic, Palisades Park, and Cliffside Park. The number of family units for these two groups exceeds 20,000 family units***. In
addition, while still in early discussion stages, PCA has had
preliminary discussions with the Attorney for the Maryland School
System and the Pennsylvania (900,000 family units) and Maryland
AFL-CIO with 125,000 family units****.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As part of its non-profit program, PCA has contracted with Palisades Medical Center and is
currently pursuing business relationships with Kimball Medical Center in Lakewood, New Jersey; Englewood Hospital; Raritan
Bay in Old Bridge; Westfield Hospital in Allentown, Pennsylvania and
Doylestown Medical Center. These organizations currently
generate over 150,000 prescriptions per year*****.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lastly, Caring People, a five state home care agency, has approached PCA concerning using its
Medicine on Time PACMed Pouch for the approximate 1,000 patients it currently services. We
estimate that this would constitute approximately 60,000 to 80,000 prescriptions per year******.
</DIV>
<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</div>
<DIV align="left" style="font-size: 10pt; margin-top: 3pt">Footnotes: *Group1; **Group 2; ***Group 3; ****Group 4; *****Group 5; and ******Group 6.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Financial Projections-Annualized First Year</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Family</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Annual</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Annual</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Group</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Units</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Prescriptions</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Sales</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Profit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>EBITA</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">9,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,350,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">450,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">9,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,350,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">450,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">180,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">18,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,700,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">900,000</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Family</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Annual</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Annual</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Group</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Units</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Prescriptions</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Sales</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Profit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>EBITA</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4*</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">562,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">56,250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">8,437,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,812,500</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">15,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">750,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">7,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,050,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">350,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,142,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">114,250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">17,137,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">5,712,500</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Assume 50% sales success rate.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Assumptions:30 Rxs per family unit; $100 per Rx; $15 Gross Profit per Rx; and $6 EBITA per
prescription.</TD>
</TR>

</TABLE>


<DIV align="left">
<A name="127"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>STOCK ISSUANCES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company was incorporated February&nbsp;26, 2008. Total authorized shares: 25,000,000. As of
December&nbsp;31, 2009, the Board of Directors approved a total of 13,630,000 shares issued and
outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer and President, Gary Sekulski, 9,500,000 shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joseph Drucker, Corporate Counsel, Secretary and Chief Financial Officer, 3,000,000 shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jan Goldberg, Executive Vice President,500,000 shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Matilda Bruno, Consultant,50,000 shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Steve Monetti, Consultant, 20,000 shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wayne Miller, Consultant, 10,000 shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scott M. Cutler purchased 20,000 shares for $10,000 as an accredited investor from the Form
D Reg 504 Private Placement Memorandum.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John R. DeSheplo purchased 20,000 shares for $10,000 as an accredited investor from the Form&nbsp;D
Reg 504 Private Placement Memorandum.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Buy Sell Pharmacy.com, Consultant, 25,000 shares.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Colonial Consulting Group LLC, Consultant, 60,000 shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kathleen and Keith Muhlmeister, accredited investors from the Form&nbsp;D Reg 504 Private
Placement Memorandum, 25,000 shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;First Time LLC Stock Purchase Agreement, 400,000 shares.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="128"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>DESCRIPTION OF SECURITIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following statements are qualified in their entirety by reference to the detailed provisions of
our Certificate of Incorporation, as amended, and By-Laws. The Shares registered pursuant to the
registration statement of which this Prospectus is a part are shares of common stock, all of the
same class and entitled to the same rights and privileges as all other shares of common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Capital Stock</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The authorized capital stock of the Company is 25,000,000 shares of common stock, with no par value
per share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As of the date of this prospectus, there are 13,630,000 shares of common stock issued outstanding.
There is no preferred stock authorized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Options and Warrants</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">There are no outstanding options or warrants or other securities that are convertible into our
common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Voting Rights</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Each shareholder is entitled to one (1)&nbsp;vote for each share of voting stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Dividend Policy</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We intend to retain and use any future earnings for the development and expansion of our business
and do not anticipate paying any cash dividends in the foreseeable future.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Transfer Agent</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The registrar and transfer agent for our common stock is Corporate Stock Transfer Inc., 3200 Cherry
Creek Drive South, Suite&nbsp;430, Denver, CO 80109.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Penny Stock Regulation</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The SEC has adopted regulations which generally define &#147;penny stock&#148; to be any equity security that
has a market price (as defined) of less than $5.00 per share or an exercise price of less than
$5.00 per share. Such securities are subject to rules that impose additional sales practice
requirements on broker-dealers who sell them. For transactions covered by these rules, the
broker-dealer must make a special suitability
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">determination for the purchaser of such securities and have received the purchaser&#146;s written
consent to the transaction prior to the purchase. Additionally, for any transaction involving a
penny stock, unless exempt, the rules require the delivery, prior to the transaction, of a
disclosure schedule prepared by the SEC relating to the penny stock market. The broker-dealer also
must disclose the commissions payable to both the broker-dealer and the registered representative,
current quotations for the securities and, if the broker-dealer is the sole market-maker, the
broker-dealer must disclose this fact and the broker-dealer&#146;s presumed control over the market.
Finally, among other requirements, monthly statements must be sent disclosing recent price
information for the penny stock held in the account and information on the limited market in penny
stocks. As the Shares immediately following this Offering will likely be subject to such penny
stock rules, purchasers in this Offering will in all likelihood find it more difficult to sell
their Shares in the secondary market.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The financial statements of the Company as of December&nbsp;31, 2008 and for the period from February
26, 2008 (inception)&nbsp;through December&nbsp;31, 2008, included in this Registration Statement have been
audited by Moore &#038; Associates Chartered Accountants, 6490 West Desert Inn Road, Las Vegas,
NV 89146, tel. 702 253 7499, and have been so included in reliance upon the report of Moore &#038;
Associates Chartered Accountants given on the authority of such firm as experts in accounting and
auditing.
</DIV>
<DIV align="left">
<A name="129"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>UNDERTAKINGS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned Registrant hereby undertakes:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To include any prospectus required by Section&nbsp;10(a)(3) OF THE Securities Act of
1922, as amended;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To reflect in the prospectus any facts or events arising after the effective
date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the
information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any deviation from
the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) (&#167;230.424)b) of
this chapter) if, in the aggregate, the changes in volume and price represent no more
than 20% change in the maximum</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in
the effective registration statement;</TD>
</TR>


<tr style="font-size: 6pt">
    <TD>&nbsp;</TD>
</tr>


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To include any material information with respect to the plan of distribution
not previously disclosed in the registration statements or any material change to such
information in the registration statement;</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Provided, however that paragraphs (1)(i), (1)(ii) and (1)(iii) do not apply if the information
required to be included in a post-effective amendment by those paragraphs is contained in periodic
reports filed by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange
Act of 1934 that are incorporated by reference in the registration statement, or is contained in a
form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement;
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>That, for the purpose of determining any liability under the Securities Act of
1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the offering.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each prospectus filed pursuant to Rule 424(b) as part of a registration
statement relating to an offering, other than registration statements relying on Rule
430B or other than prospectuses filed in reliance on Rule&nbsp;430A, shall be deemed to be
part of and included in the registration statement as of the date it is first used
after effectiveness. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a
document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will as to a
purchaser with time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part
of the registration statement or made in any such document immediately prior to such
date of first use.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For determining liability of the undersigned under the Securities Act to any
purchaser in the initial distribution of the securities, the undersigned undertakes
that in a primary offering of securities of the undersigned pursuant to this
registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by
means of any of the following</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>communications, the undersigned will be a seller to the purchaser and will be
considered to offer or sell such securities to such purchaser:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any preliminary prospectus of prospectus of the undersigned small business
issuer relating to the offering required to be filed pursuant to;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any free writing prospectus relating to the offering prepared by or on behalf
of the undersigned small business issuer or used or referred to by the undersigned
small business issuer;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The portion of any other free writing prospectus relating to the offering
containing material information about the undersigned small business issuer or its
securities provided by or on behalf of the undersigned small business issuer; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any other communication that is an offer in the offering made by the
undersigned small business issuer to the purchaser.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left">
<A name="130"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused
this registration statement to be signed on its behalf by the undersigned, on April&nbsp;22, 2009.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><U>Healthcare Corporation of America</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" colspan="3"><DIV style="margin-left:60px; text-indent:-0px">(Registrant)</div></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gary
Sekulski<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Gary
Sekulski, President,<BR>
Chief Executive Officer<BR>
Chairman, Board of Directors
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, this registration statement has
been signed by the following persons in the capacities and on the dates indicated.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">/s/&nbsp;Gary Sekulski&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President, CEO, Chairman of<BR>
Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&nbsp;&nbsp;&nbsp;(Signature)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&nbsp;&nbsp;&nbsp;(Title)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">April&nbsp;22, 2009
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="131"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>POWER OF ATTORNEY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>KNOW ALL MEN BY THESE PRESENTS</B>, that each person whose signature appears below constitutes and
appoints Patrick C. Brooks and each of them, his true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution for him and in his name, place and stead, in any and
all capacities (including his capacity as a director and/or officer of Healthcare Corporation of
America) to sign any or all amendments (Including post-effective amendments) to this registration
statement and any and all additional registration statements pursuant to rule 462(b) of the
Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other
documents in connection therewith, with the SEC, granting unto each said attorneys-in-fact and
agents, and each of them, full power and authority to do an perform each and every act and thing
requisite and necessary to be done in and about the premises, as fully to all intents and purposes
as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents or any of them, of their or his substitute or substitutes, may lawfully do or cause to
be done by virtue hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with the requirements of the Securities Act of 1933, as amended, this
registration statement was signed below by the following persons in the capacities and on the dates
stated.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gary Sekulski&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Gary Sekulski
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President, Chief Executive Officer<br>
Chairman, Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dated:
April 20, 2009
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>and SUBSIDIARY</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>(A DEVELOPMENT STAGE COMPANY)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>DECEMBER
31, 2008</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">
<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY<BR>
(A DEVELOPMENT STAGE COMPANY)<BR>
CONSOLIDATED FINANCIAL STATEMENTS<BR>
FOR THE PERIOD FROM INCEPTION ON FEBRUARY 26, 2008 THROUGH<BR>
DECEMBER 31, 2008</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="0">Page No.</TD>
    <TD>&nbsp;</TD>

</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#101">Report of Independent Registered Public Accounting Firm</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt">
<TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#102">Consolidated Balance Sheet</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt">
<TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#103">Consolidated Statement of Operations</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt">
<TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#104">Consolidated Statement of Cash Flows</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt">
<TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#105">Consolidated Statement of Stockholders&#146; Equity</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt">
<TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#106">Notes to Consolidated Financial Statements</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6-10</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>MOORE &#038; ASSOCIATES, CHARTERED</B><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><I>ACCOUNTANTS AND ADVISORS</I></U><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>PCAOB REGISTERED</I>

</DIV>

<DIV align="left">
<A name="101"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><U><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>To the Board of Directors<BR>
Healthcare Corporation of America<BR>
(A Development Stage Company)</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have audited the accompanying consolidated balance sheet of Healthcare Corporation of America (A
Development Stage Company) as of December&nbsp;31, 2008 and the related consolidated statements of
operations, stockholders&#146; equity and cash flows for the period from inception on February&nbsp;26, 2008
through December&nbsp;31, 2008. These financial statements are the responsibility of the Company&#146;s
management. Our responsibility is to express an opinion on these financial statements based on our
audits.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We conducted our audits in accordance with standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement. An
audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In our opinion, the financial statements referred to above present fairly, in all material
respects, the financial position of Healthcare Corporation of America (A Development Stage Company)
as of December&nbsp;31, 2008 and the related consolidated statements of operations, stockholders&#146; equity
and cash flows for the period from inception on February&nbsp;26, 2008 through December&nbsp;31, 2008, in
conformity with accounting principles generally accepted in the United States of America.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The accompanying consolidated financial statements have been prepared assuming that the Company
will continue as a going concern. As discussed in Note 1 to the financial statements, the Company
is in its development stage, has no established source of revenue, and is dependent on its ability
to raise capital from shareholders or other sources to sustain operations. These factors raise
substantial doubt about its ability to continue as a going concern. Management&#146;s plans concerning
these matters are also described in Note 1. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>/s/ Moore &#038; Associates, Chartered</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Moore &#038; Associates Chartered<BR>
Las Vegas, Nevada<BR>
April&nbsp;16, 2009

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><I>6490 West Desert Inn Road, Las Vegas, NV 89146 (702)&nbsp;253-7499 Fax (702)&nbsp;253-7501</I></U></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY<BR>
(A Development Stage Company)</B>
</DIV>

<DIV align="left">
<A name="102"></A>
</DIV>
<DIV align="center" style="font-size: 10pt"><B>CONSOLIDATED BALANCE SHEET</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">December 31, 2008</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>Assets</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">14,209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">14,209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>Liabilities and Stockholders&#146; Deficit</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">79,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued Officers&#146; Compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">369,500</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Related Party Payables</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,101</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">453,601</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">453,601</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stockholders&#146; deficit:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Common stock, no par value,
25,000,000 shares authorized, 13,630,000 shares issued</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">301,400</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deficit accumulated during the developmental stage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(740,792</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total stockholders&#146; deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(439,392</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total Liabilities and Stockholders&#146; Deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">14,209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See
notes to financial statements.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY<BR>
(A Development Stage Company)</B>
</DIV>

<DIV align="left">
<A name="103"></A>
</DIV>
<DIV align="center" style="font-size: 10pt"><B>CONSOLIDATED STATEMENT OF OPERATIONS</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">From inception on</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">February 26, 2008</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">through December 31, 2008</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cost of sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Gross profit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Officer&#146;s salaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">466,300</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Consulting fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">137,600</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Administrative expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,178</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Professional fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">635,078</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss from Operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(635,078</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Write-off of loan balance due from LTC Specialists, LLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(105,714</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Provision for Income Tax</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(740,792</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.06</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted-average number of common shares outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,777,330</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See
notes to financial statements.

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY<BR>
(A Development Stage Company)</B>
</DIV>

<DIV align="left">
<A name="104"></A>
</DIV>
<DIV align="center" style="font-size: 10pt"><B>CONSOLIDATED STATEMENT OF CASH FLOWS</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">From inception on</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">February 26, 2008</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">through December 31, 2008</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Operating activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(740,792</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Adjustments to reconcile net loss to net cash used in operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Services paid for with common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">58,900</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Write-off of loan balance due from LTC Specialists, LLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">105,714</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Changes in assets and liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Increase in accrued expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">79,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Increase in accrued officers&#146; compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">369,500</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><B>Net cash used in operating activities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(127,678</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Investing activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Increase in loan to LTC Specialists, LLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(105,714</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><B>Net cash used in investing activities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(105,714</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Financing activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Increase in Related Party payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,101</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Increase in stock sold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">242,500</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><B>Net cash provided by financing activities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">247,601</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net increase (decrease)&nbsp;in cash</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash at beginning of period</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash at end of period</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">14,209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash paid during the period for:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Supplemental disclosure of non-cash financing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock for Services, Founders shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,300</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock for Services, 60,000 shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">57,600</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See
notes to financial statements.

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY<BR>
(A Development Stage Company)</B>
</DIV>

<DIV align="left">
<A name="105"></A>
</DIV>
<DIV align="center" style="font-size: 10pt"><B>CONSOLIDATED STATEMENT OF STOCKHOLDERS&#146; EQUITY</B></DIV>


<DIV align="center" style="font-size: 10pt"><B>FOR THE PERIOD FROM INCEPTION ON FEBRUARY 26, 2008 THROUGH DECEMBER 31, 2008</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Deficit</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Accumulated During</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Common Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Subscriptions</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Development</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Total</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Issued</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amount</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Receivable</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Stage</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Equity</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="11" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Founders Shares:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Valued at $0.0001</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">1,300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,300</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Private Placements:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">February&nbsp;26, 2008 $0.50 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">February&nbsp;29, 2008 $0.50 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">February&nbsp;26, 2008 $0.20 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Shares for Services, 3/31/08:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Colonial Consulting Group, $0.50 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Buy Sell Pharmacy.com, $0.50 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,500</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Others, $0.50 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,100</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Shares for Expenses Paid 3/31/08</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(42,233</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(42,233</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Private Placement:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">July&nbsp;3, 2008 $0.50 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,500</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Stock Issued for cash:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">August&nbsp;28, 2008 $0.50 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">200,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px"><B>Services performed for the period ended 12/31/08</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42,233</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42,233</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(740,792</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(740,792</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="11" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Balance,
December&nbsp;31, 2008</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,630,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">301,400</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(740,792</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(439,392</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See notes to financial statements.

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 5<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY<BR>
(A DEVELOPMENT STAGE COMPANY)</B>
</DIV>

<DIV align="left">
<A name="106"></A>
</DIV>
<DIV align="center" style="font-size: 10pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Note 1: Summary of Significant Accounting Policies</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Business Activity</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Healthcare Corporation of America (HCA)&nbsp;was incorporated in New Jersey on February&nbsp;26, 2008
with the intent to house institutional pharmacy, mail order pharmacy, and central fill
pharmacy services in one closed pharmacy
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Private placements on February 26, 2008 and February&nbsp;29, 2008, raised a total of $35,000 A
private placement on July&nbsp;3, 2008 raised a total of $12,500. HCA raised $200,000 on August&nbsp;28,
2008 through a stock purchase agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company is in its development stage. This stage is characterized by significant expenditures
for the design and development of the Company&#146;s products and
obtaining financing. Accordingly,
the financial statements are presented in accordance with Statement of Financial Accounting
Standards (SFAS)&nbsp;No. 7<I>, Accounting and Reporting by
Development-State Enterprises </I>(SFAS 7).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The accompanying financial statements have been prepared assuming that the company will
continue as a going concern As the company is in its development stage, it has no established
source of revenue and is dependent on its ability to raise capital from shareholders or other
sources to sustain operations. These factors raise substantial doubt that the company will be
able to continue as a going concern. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Principles of Consolidation</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The consolidated financial statements include the accounts of HCA and its wholly owned
subsidiary, Prescription Corporation of America, which was also formed with the intent to
enter into the pharmaceutical sales industry. All material intercompany accounts and
transactions have been eliminated in consolidation
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Cash and Cash Equivalents</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cash and cash equivalents consist of cash on hand and cash in banks, and are stated at cost,
which approximates fair market value. The Company considers all highly liquid debt
instruments with original maturities of three months or less to be cash equivalents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Accounts Receivable and Allowance for Doubtful Accounts</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Trade
accounts receivable are recorded at the invoiced amount and do not bear interest. The
allowance for doubtful accounts is the Company&#146;s best estimate of the amount of probable
credit losses in the Company&#146;s existing accounts receivable The Company had $0 accounts
receivable at December&nbsp;31, 2008, and therefore the allowance for doubtful accounts at December
31, 2008 is also $0 Additionally, the Company&#146;s bad debt expense for the period ended December&nbsp;31, 2008 was $0. The Company does not have any off-balance-sheet credit exposure related to
its customers
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY<BR>
(A DEVELOPMENT STAGE COMPANY)<BR>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Note 1: Summary of Significant Accounting Policies (continued) </U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Use of Estimates in Preparation of Financial Statements</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The preparation of financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and
assumptions that affect the reported amounts of certain assets and liabilities and disclosures of
contingent assets and liabilities at the date of the financial statements and the related reported
amounts of revenues and expenses during the reporting period. Actual results could differ from
those estimates. Management believes that its estimates are reasonable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Concentrations of Credit Risk</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Financial instruments, which potentially subject the Company to concentrations of credit risk,
consist principally of cash. The Company generally maintains its cash balances at one
financial institution. At times, such investments may be in excess of the Federal Deposit
Insurance Corporation limit of $250,000. At December&nbsp;31, 2008, no cash investment account was
in excess of the insured limit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">The Company had $0 gross revenue for the period ended December&nbsp;31, 2008
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Advertising and Promotions</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Advertising and promotions are expensed as incurred and included in operating expenses. For
the period ended December&nbsp;31, 2008 advertising and promotion
expenses were $0.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Income Taxes</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company follows the liability method of accounting for income taxes in accordance
with SFAS No 109, Accounting for Income Taxes. Under this method, deferred income taxes
are recorded based upon the differences between the financial reporting and tax bases of
assets and liabilities and are measured using the enacted tax rates and laws that will be
in effect when the underlying assets or liabilities are recovered or settled.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Valuation allowances are established when necessary to reduce deferred tax assets to the
amount expected to be realized
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY<BR>
(A DEVELOPMENT STAGE COMPANY)<BR>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Note 2: Commitments and Contingencies</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On February&nbsp;6, 2008, prior to the inception of HCA, the current management of HCA negotiated
and signed a three year agreement with Colonial Consulting Group (&#147;Colonial&#148;) where Colonial
would perform certain consulting and business development services for HCA Under the terms
of the agreement, Colonial will be issued 60,000 common shares of HCA and HCA will pay
Colonial the sum of $5,000 per month for the first six months of the contract for services
performed by Colonial. For the remaining six months of the year, HCA will pay Colonial $10,000
per month for services rendered. For the second and third years of the agreement, HCA will pay
Colonial $15,000 and $20,000 per month, respectively for services rendered. Over the term of
the agreement, Colonial has the option to receive an equivalent portion of common stock in
place of payment. In addition, HCA will pay Colonial twenty five cents per prescription for
all business placements in HCA&#146;s market sectors Colonial is also entitled to a finder&#146;s fee
equal to five percent of invested money for any additional capital Colonial secures in HCA&#146;s
interest. Colonial may also acquire the equivalent of five percent of the finder&#146;s fee in
common stock at the initial rate of fifty cents per share
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Note 3: Executive Compensation</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company entered into formal employment contracts with its senior officers. These contracts
commenced October&nbsp;1, 2008 and expire after four years. Prior to October&nbsp;1, 2008, management
has estimated an amount that the officers earned on a monthly basis and has accrued the
officers&#146; salaries to date in the financial statements. The officers began the process of
developing a business plan for the company in October&nbsp;1, 2007; therefore, management has paid
or accrued fifteen months of officers&#146; salaries Officers&#146; salary expense for the period of
inception through December&nbsp;31, 2008 was $465,000, which includes $369,500 of accrued
officer&#146;s compensation expense and $95,500 of payments to officers since inception. The Board
of Directors of HCA, at a board meeting held March&nbsp;17, 2009, unanimously voted to defer the
accrued salaries due to officers. The board will reinstate the deferred accrued salaries of
the officers only when HCA&#146;s cash flow turns positive. The following summarizes the executive
compensation to senior management:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY<BR>
(A DEVELOPMENT STAGE COMPANY)<BR>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Sekulski</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Drucker</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Goldberg</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Total</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accrual for services through 3/31/08</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">120,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">30,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">60,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">210,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accrual for services 4/1 - 6/30/08</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accrual for services 7/1 - 9/30/08</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accrual for services 10/1 - 12/31/08</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">165,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD NOWRAP><DIV style="margin-left:15px; text-indent:-15px">Total officers&#146; compensation
expense inception through December
31, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">240,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">90,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">135,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">465,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Payments for services 2/26 - 3/31/08</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">32,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Payments for services 4/1 - 6/30/08</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,500</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Payments for services 7/1 - 12/31/08</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total payments for services
inception through December&nbsp;31, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">89.500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5.000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">95,500</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Founders&#146; service expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.300</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Founders&#146; shares for services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,000,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Note 4: Loan with LTC Specialists</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In September&nbsp;2008, HCA loaned $140,000 to Long Term Care Specialists, LLC
(&#147;LTC&#148;), a New Jersey based limited liability corporation in the pharmaceutical
sales business. No interest was accrued on these loans HCA has received
information that LTC has ceased operations due to its continued inability to meet
its commitments. It is apparent that HCA&#146;s loan receivable from LTC is
uncollectible. Therefore HCA will apply its loan payable of $34,286 to LTC
against the $140,000 loan receivable resulting in a write-off of $105,714.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Note 5: Related Party Payables</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HCA has loans with certain officers of the Company As of December&nbsp;31, 2008 the
balance of these loans was $5,101. These loans do not bear interest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Note 6: Stockholders&#146; Equity</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On
February&nbsp;26, 2008, the date of inception, 520,000 shares were issued for cash.
On February&nbsp;26, 2008, an additional 50,000 shares were issued for cash. On
February&nbsp;29, 2008, an additional 20,000 shares were issued for
cash. These three
private placements raised a total of $35,000.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY<BR>
(A DEVELOPMENT STAGE COMPANY)<BR>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Additionally,
on March 31, 2008, 13,000,000 shares were subscribed as founders&#146; shares at a
value of $1,300, and 115,000 shares were subscribed in exchange for services rendered, valued at
$57,600. Related capitalized costs of $42,233 were designated as subscriptions receivable at
March&nbsp;31, 2008. For the nine months ending December&nbsp;31, 2008, all of the previously
capitalized costs were expensed for consulting services performed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On
July&nbsp;3, 2008 25,000 shares of common stock were issued for cash. On August&nbsp;28, 2008,
400,000 shares of common stock were issued for cash. These two stock issuances raised a total
of $212,500
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Note
7: Related Parties</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Gary Sekulski and Jan Goldberg have been officers of HCA since its inception and held
officer positions at LTC until October&nbsp;2008 when they terminated their employment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LTC had a consulting arrangement with certain officers of HCA and Colonial whereby
services were provided to LTC in 2008 for a fee. In accordance with this arrangement, this
fee was paid directly to the officers of HCA and to Colonial who performed the consulting
work.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

 <DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBITS</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Healthcare Corporation of America Certificate of Incorporation</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prescription Corporation of America Certificate of Incorporation</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Healthcare Corporation of America By-Laws</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prescription Corporation of America By-Laws</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Colonial Consulting Group, LLC Agreement</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Opinion of Joseph Drucker</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consent of Joseph Drucker (Included as part of Exhibit&nbsp;5.1)</TD>
</TR>


<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Agreement with Toms River School District*</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Agreement with Phillipsburg School District*</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>To be  filed as an amendment </TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
[{"type": "S-1", "sequence": "1", "filename": "y76306sv1.htm", "description": "FORM S-1", "secsgml_size_bytes": 286017}]
{"company-data": {"conformed-name": "HEALTHCARE CORP OF AMERICA", "cik": "0001430762", "assigned-sic": "5912", "irs-number": "000000000", "state-of-incorporation": "DE"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-158702", "film-number": "09763858"}, "business-address": {"street1": "36 KEVIN DRIVE", "city": "FLAMDERS", "state": "NJ", "zip": "07836", "phone": "973-796-4216"}, "mail-address": {"street1": "36 KEVIN DRIVE", "city": "FLAMDERS", "state": "NJ", "zip": "07836"}}
S-1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-1
GENERAL FORM FOR REGISTRATION OF SECURITIES OF SMALL BUSINESS
ISSUERS
Under Section 12(G) of the Securities Exchange Act of 1933
HEALTHCARE CORPORATION OF AMERICA
(Name of Small Business Issuer in its Charter)
NEW JERSEY
26 2071625
(State of other jurisdictional
incorporation or organization)
(I.R.S. Employee Identification No.)
2833
(Primary Standard Industrial Classification Code Number)
Gary Sekulski, CEO and President, 36 Kevin Drive, Flanders, New Jersey 07836
Tel 973 796 4216
(Address , including zip code, and telephone number, including area code, of registrants'
principal executive offices)
Copy to
Joseph Drucker, Attorney, 43 Sawgrass Street, Jackson, New Jersey 08527
732 928 5965
(Name, address, including zip code, and telephone number, including area code, of agent for
services)
Approximate date of commencement of proposed sale to the public: as soon as practicable after
this registration becomes effective.
If any of the securities being registered on this form are to be offered on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
þ
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)
under the Securities Act, check the following box and list the Securities Act Registration
statement number of earlier effective registration statement for the same offering.
o
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act,
check the following box and list the Securities Act Registration statement number of earlier
effective registration statement for the same offering.
o
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act,
check the following box and list the Securities Act Registration statement number of earlier
effective registration statement for the same offering.
o
*Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated
filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer
o
Accelerated filer
o
Non-accelerated filer
o
Smaller reporting company
þ
(Do not check if a smaller reporting company)
CALCULATION OF REGISTRATION FEE
Proposed
Proposed
Title of
maximum
maximum
securities
Amount
offering
Aggregate
Amount of
to be
to be
Price
offering
registration
registered
registered
per share
price
fee
Common
13,630,000
$0.50
$6,815,000
$380.28
Up to 13,630,000 shares of our common stock may be sold by the selling shareholders to the public
at a fixed price of $0.50 per share until such time as the shares of our common stock are quoted on
the NASD Over-the Counter Bulletin Board ("Board") or listed on an exchange. Although we intend to
apply for quotation of our common stock on the OTCBB, public trading of our common stock may never
materialize. If our common stock becomes quoted on the OTCBB, then the sale price to the public
will vary according to prevailing market prices or privately negotiated prices by the selling
shareholders.
The Company hereby amends this registration statement on such date or dates as may be necessary to
delay its effective date until the Company shall file a further statement which specifically states
that this registration statement shall become effective on such date as the Commission, acting
pursuant to said Section 8(a) of the Securities Act of 1933 or until the registration statement
shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may
determine.
PROSPECTUS SUBJECT TO COMPLETION, DRAFTED APRIL, 2009
HEALTH CARE CORPORATION OF AMERICA
This prospectus relates to the resale, form time to time, of up to 13,630,000 shares of our common
stock at $0.50 by the selling shareholders named in the "Selling Shareholders" section of this
prospectus. Healthcare Corporation of America will not receive any proceeds from this offering and
has not made any arrangements for the sale of these securities. See "Risk Factors" commencing on
page 8 for a full discussion of the risks involved in this offering.
Proceeds to Selling
Offering Price
Commissions
Shareholders
Per Share
$
0.50
N/A
$
0.50
Total
$
6,815,000
N/A
$
6,815,000
The information in this prospectus may be changed. We may amend or supplement this prospectus from
time to time by filing amendments or supplements as required. You should read the entire
prospectus and any amendments of supplements carefully before you make your investment decision.
This prospectus is not an offer to sell our securities and it is not soliciting an offer to buy our
securities in any state where the offer or sale is not permitted.
Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any
representation to the contrary is a criminal offence.
The selling stockholders or their permitted transferees or other successors in interest may, but
are not required to, sell their holdings at a fixed price of $0.50 per share until our shares are
quoted on the OTC Bulletin Board. Thereafter they may sell their holdings in a number of different
ways and at varying prices as determined by the prevailing market price for the shares or,
privately as negotiated prices. See "Plan of Distribution"
on Page 12 for a description of how
the selling stockholders may dispose of the shares covered by this prospectus. We do not know when
or in what amount the selling stockholders may offer the shares for sale.
We will not receive any of the proceeds from sales of shares made by the selling stockholders
pursuant to this prospectus. We have agreed to pay certain expenses related to the registration of
the shares pursuant to the registration statement of which this prospectus forms a part.
1
These shares are presently not traded on any market or securities exchange. We cannot assure you
that a market maker will undertake to file the necessary documents with The Financial Industry
Regulatory Authority (FINRA") which operates the OTC Electronic Bulletin Board, nor can we assure
you that such an application for quotation will be approved.
THE COMPANY IS CONSIDERED TO BE IN UNSOUND FINANCIAL CONDITION. PERSONS SHOULD NOT INVEST UNLESS
THEY CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENTS.
THE PURCHASE OF THE SECURITIES OFFERED THROUGH THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. YOU
SHOULD CAREFULLY CONSIDER THE FACTORS DESCRIBED IN THE "RISK FACTORS" SECTION BEGINNING ON PAGE 8
OF THIS PROSPECTUS.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR
DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
2
TABLE OF CONTENTS
PROSPECTUS SUMMARY
4
THE OFFERING
4
SUMMARY FINANCIAL INFORMATION
5
RISK FACTORS
6
FORWARD-LOOKING STATEMENTS
8
USE OF PROCEEDS
9
DETERMINATION OF OFFERING PRICE
9
DILUTION
9
SELLING SECURITY HOLDERS
10
PLAN OF DISTRIBUTION
12
SELLING SHAREHOLDER'S "UNDERWRITER" STATUS: PROSPECTUS DELIVERY REQUIREMENT
13
LEGAL PROCEEDINGS
15
DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS
16
COMMITTEES OF THE BOARD OF DIRECTORS
19
INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS
19
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
20
DESCRIPTION OF CAPITAL STOCK
21
DIVIDEND POLICY
22
LEGAL MATTERS
22
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
23
MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
23
EXPERTS
24
INDEMNIFICATION
25
AVAILABLE INFORMATION
27
BUSINESS
27
EXECUTIVE SUMMARY
28
STOCK ISSUANCES
31
DESCRIPTION OF SECURITIES
33
UNDERTAKINGS
34
SIGNATURES
36
POWER OF ATTORNEY
37
FINANCIAL STATEMENTS
F-1
EX-3.1
EX-3.2
EX-3.3
EX-3.4
EX-3.5
EX-5.1
You should rely only on the information contained in this prospectus and in any accompanying
prospectus supplement. We have not, and the Selling Shareholders have not, authorized anyone to
provide you with information different from the information contained in this prospectus. The
information in this prospectus is accurate only as of the date of this prospectus, regardless of
when this prospectus is delivered or when any dale of our common stock occurs.
3
PROSPECTUS SUMMARY
The following summary highlights selected information contained in this registration statement.
This summary does not contain all the information you should consider before purchasing the
securities from the selling shareholders. Before making an investment decision, you should read
the entire prospectus carefully including the "RISK FACTORS" SECTION, THE FINANCIAL STATEMENTS AND
THE NOTES TO THE FINANCIAL STATEMENTS. As used throughout this prospectus, the terms "Healthcare,"
the "Company," "we," "us," and "our" refer to Healthcare Corporation of America. All dollar
amounts in this prospectus are in U.S. dollars unless otherwise stated.
HCA is a product development and marketing company that has developed a new business model that
will reduce and control pharmacy costs for non-profit organizations.
Healthcare Corporation of America was incorporated under the laws of New Jersey, February 26, 2008.
As of the date specified all cash has been raised from the issuance of securities. $32,500 from
sale of shares through a Private Placement Memorandum Form D filing. $200,000 from a Stock Purchase
Agreement with First Time II LLC.
Our administrative office is located at 36 Kevin Drive, Flanders, New Jersey 07836. The company
year end is December 31, 2008.
THE OFFERING
Securities Being Offered
Up to 13,630,000 shares of our
common stock held by the HCA
shareholders named in this
prospectus.
Offering Price and Plan of Distribution
The selling shareholders named in
this prospectus will sell 13,630,000 shares of our common
stock offered under this
prospectus at an offering price of$0.50 per
share unless the offered
shares are quoted on the
Over-the-Counter Bulletin Board.
We intend to apply to the
Over-the-Counter Bulletin Board to
allow for the trading of our
common stock when we become a
reporting entity under the
Securities
4
Exchange Act of 1934.
If our common stock becomes so
traded and a market for the stock
develop, the actual price of our
stock will be determined by
prevailing market prices at the
time of sale or by private
transactions negotiated by the
shareholders named in this
prospectus. The offering price
would thus be determined by market
factors and the independent
decisions of the selling
shareholders in this prospectus.
Minimum Number of Shares to be sold in
this Offering
None
Securities issued and to be issued
13,600,000 shares of our common
stock are issued and outstanding
as of the date of this prospectus.
Use of Proceeds
We will not receive any proceeds
from the sale of the common stock
listed in this prospectus by the
shareholders. The selling
shareholders will receive the
proceeds from any resale of our
common stock covered by the
prospectus.
SUMMARY FINANCIAL INFORMATION
As of Period
Balance Sheet Data
Ended December 31, 2008
Cash
$
14,209
Total Assets
$
14,209
Total Liabilities
$
453,601
Stockholders' Deficit
$
(439,392
)
For the Period from Inception
On February 26, 2008
Statement of Operations Data
To December 31, 2008
Revenue
$
0
Total Expenses
$
635,078
Net Income (Loss)
$
(740,792)
5
Investment in HCA involves significant risks. The Company will not be raising any funds in this
offering. We will need to raise additional funds to meet future requirements.
RISK FACTORS
There is no assurance that our business will be profitable. An investment in our common stock
involves high degrees of risk. You should carefully consider the risks described below and the
other information in this prospectus before investing in our common stock. If any of the following
risks occur, our business operating results and financial condition could be seriously harmed.
You cannot evaluate the investment merits of our Company because we have no operating history.
We were incorporated in February 26, 2008 and we have not started our proposed business operations
or realized any revenues, which makes it difficult to evaluate the investment merits of our
Company. We are a start-up company. We have no operating history and we do not have any business
prior to our organization. As of December 31, 2008 we incurred total expenses of $635,078.
We may not be able to continue as a going concern if we do not obtain additional financing.
Because our lack of sufficient funds and short operating history incurring only expenses, and no
revenues, our independent accountants' audit report states that there is substantial doubt about
our ability to continue as a going concern. Our independent auditor in their audit report have
stated that we incurred only losses since our inception raising substantial doubt about our ability
to continue as a going concern. Therefore, our ability to continue as a going concern is highly
dependent upon obtaining additional financing for our planned operations. As of the date hereof,
all our cash has been raised from the issuance of securities.
We are highly dependent on our senior management. The loss of our executive officers could hinder
our ability to pursue our stated plan of operations and obtain debt or equity financing, if and
when required.
We believe that our continued success depends to a significant extent upon the efforts and
abilities of our senior management and in particular, Gary Sekulski, CEO. Mr. Sekulski has been in
the prescription drug industry for over 35 years. We believe that the loss of Mr. Sekulski's
business and management experience could hinder our ability to pursue our stated plan of operations
and obtain debt or equity financing, if and when required.
6
Risks Associated with this Offering
Because we have nominal assets, we are considered a "shell company" and will be subject to more
stringent reporting requirements.
The Securities and Exchange Commission ("SEC") adopted rules which defines (as defined by Rule 405
of the Securities Act and Exchange Act Rule 12b-2) a shell company as a registrant that has no or
nominal operations, and either (a) no or nominal assets; (b) assets consisting solely of cash and
cash equivalents; or (c) assets consisting of any amount of cash and cash equivalents and nominal
other assets. Our balance sheet states that we have cash as our only asset therefore, we are
defined as a shell company.
Our two directors, Gary Sekulski and Joseph Drucker, control approximately 92% of our outstanding
shares of common stock. The interests of our directors may not be, at all times, the same as that
of other shareholders. Since our directors are not simply passive investors but are also our
directors and officers of the company, their interests as management may, at times, be adverse to
those of passive investors. Where those conflicts exist, our shareholders will be dependent upon
our management exercising, in a manner fair to all of our shareholders, his fiduciary duties as an
officer or as a member of our board of directors. Also, management will have the ability to
significantly influence the outcome of most corporate actions requiring shareholder approval,
including the merger of Services with or into another company, the sale of all or substantially all
of our assets and amendments to our articles of incorporation. This concentration of ownership
with our directors may also have the effect of delaying, deferring or preventing a change in
control of HCA, which may be disadvantageous to minority shareholders.
If the shareholders sell a large number of shares all at once or in blocks, the market price of our
shares would most likely decline.
Our common stock is presently not traded or quoted on any market or securities exchange, but should
a market develop, shares sold at a price below the current market price at which the common stock
is quoted will cause that market price to decline. Moreover, the offer or sale of a large number
of shares at any price may cause the market price to fail. The shares of common stock covered by
this prospectus represent 100% of the common shares outstanding as of the date of this prospectus.
Because there is no public trading market for our common stock, you may not be able to resell your
shares.
7
We have
very limited financial resources. As of December 31, 2008 we had
total assets of
$14,209 consisting of cash on hand and an accumulated deficit of
($439.392). Our auditor has
issued a "going concern" opinion and has expressed substantial doubt about our ability to continue
as a going concern. Our continuance as a going concern is dependent on our ability to obtain
equity or debt financing and generate profitable revenues. Even if we do obtain adequate capital,
the outcome or success cannot be predicted with any certainty at this time. Our financial
statements do not include any adjustments for these uncertainties. If we cannot continue as a
viable entity, we will suspend or cease operations. If this were to occur, stockholders may lose
their entire investment.
Further, our company plans to have its shares quoted on the OTC Bulletin Board. There are no
assurances that we will be successful in listing our shares. There is currently no public trading
market for our common stock. Therefore there is no central place, like a stock exchange or
electronic trading system, to resell your shares. If you do want to resell your shares, you will
have to locate a buyer and negotiate your own sale. Therefore, you may not be able to resell your
shares.
FORWARD-LOOKING STATEMENTS
Some of the statements under the "Prospectus Summary," "Risk Factors," "Plan of Operations,"
"Business" and elsewhere in this prospectus constitute forward-looking statements. These
statements involve known and unknown risks, uncertainties and other factors that may cause our
actual results, levels of activity, performance, or achievements to be materially different from
any future results, levels of activity, performance, or achievement expressed or implied by such
forward-looking statements. Such factors include, among other things, those listed under "Risk
Factors" and elsewhere in this prospectus.
In some cases, you can identify forward-looking statements by terminology such as "may," "should,"
"could," "intend," "expects," "plan," "anticipates," "believes," "estimates," " predicts,"
"potential," or "continue" or the negative of such terms or other comparable terminology.
Although we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness
of such statements. We are under no duty to update any of the forward-looking statements after the
date of this prospectus.
8
USE OF PROCEEDS
The Company will not receive any proceeds from the registration of common shares in this
prospectus.
DETERMINATION OF OFFERING PRICE
Offering price of our common shares by which our shareholders may sell their shares prior to the
quotation of the Company's shares on the OTC Bulletin Board ("OTCBB") will be arbitrarily chosen
based on our internal assessment of what the market would support. Our founding shareholders
purchased 13,000,000 of our common shares at a price of $0.0001 per share on March 10, 2008. The
offering price of our shares are substantially higher than the price paid by our founding
shareholders, and exceeds the per share value of our net tangible assets.
You may also suffer additional dilution in the future from the sale of additional shares of common
stock or other securities, if the need for additional financing forces HCA to make such sales.
Investors should be aware of the risk of judging the real or potential future market value, if any
of our common stock by comparison to the offering price.
There is no established public market for the shares of common stock being registered. As a
result, the offering price and other terms and conditions relative to the shares of common stock
offered hereby have been arbitrarily determined by us and do not necessarily bear any relationship
to assets, earnings, book value or any other objective criteria of value. In addition, no
investment banker, appraiser or other independent, third party has been consulted concerning the
offering price for the shares or the fairness of the price used for the shares.
We intend to apply to the OTCBB to allow the quotation of our common stock upon HCA becoming a
reporting entity under the Securities Exchange Act of 1934. We intend to file this S-1
registration statement under the Exchange Act with the effectiveness of the registration statement
of which this prospectus forms a part. If our common stock becomes as quoted and a market for the
stock develops, the actual price of stock will be determined by prevailing market prices at the
time of sale of by private transactions negotiated by the selling shareholders. The offering price
would thus be determined by market factors and the independent decisions of the selling
shareholders.
DILUTION
9
The common stock to be sold by the selling shareholders is common stock that is currently issued
and outstanding. Accordingly, there will be no dilution to our existing shareholders.
SELLING SECURITY HOLDERS
The selling shareholders named in this prospectus are offering 13,630,000 share of our common stock
acquired by the selling shareholders from HCA in offerings that were exempt from registration.
1.
The selling shareholders, three founding shareholders, acquired 13,000,000 shares of
our common stock from us at a price of $0.0001 per share that was exempt from registration
on March 10, 2008.
2.
Three selling shareholders acquired 65,000 shares of HCA common stock from a Form D
Reg-504 Private Placement Memorandum at $0.50 per share.
3.
First Time II LLC purchased 400,000 shares under a Stock Purchase Agreement dated
August 28, 2008 for a purchase price of $0.50 per share.
The term "selling shareholders" includes donees, pledges, transferees or other
successors-in-interest selling shares received after the date of this prospectus from a selling
shareholder as a gift, pledge or other non-sale related transfer.
Based on information provided to us by the selling shareholders, the following table provides
information as of December 31, 2008, regarding the number of shares of our common stock held by
each of the selling shareholders as of the date hereof, including: (1) the total number of shares
that are to be offered by each; (2) the percentage owned by each prior to the offering; (3) the
percentage owned by each upon completion of the offering; and (4) the identity of the beneficial
holder of any entity that owns the shares.
Except as disclosed in the table below, to the best knowledge of management of the Company, the
named party beneficially owns and has sole voting and investment power over all shares or rights to
these shares. The numbers in the table assume that none of the selling shareholders sells shares
of common stock not being offered in this prospectus or purchases additional shares of common
stock, and assumes that all shares offered are sold.
Except as disclosed below, none of the selling shareholders
(i)
has had a material relationship with us or any of our affiliates other than as
a security holder at any time within the past three years; or *
10
(ii)
has ever been one of our officers or directors.
*
Except for # 1, 2 and 3 who are officers and directors
Shares Beneficially Owned
Total Shares
Shares Beneficially Owned
Name and Address of
Prior to the Offering
Offered by this
After the Offering
Selling Shareholders
Number
Percent
Prospectus
(1)
Number
Percent
1
Gary Sekulski
9,500,000
9,500,000
0.0
%
56 Kevin Drive
Flanders, NJ 07838
2
The Joseph Drucker
3,000,000
3,000,000
0.0
%
1995 Trust
c/o Thomas Fortin Trustee
165 East 66 Street
New York, NY
3
Jan Goldberg
500,000
500,000
0.0
%
4
Matilda Bruno
50,000
50,000
0.0
%
5
Steve Monetti
20.000
20.000
0.0
%
6
Colonial Consulting Group LLC
60,000
60,000
0.0
%
7
Buy and Sell Pharmacy.com
25,000
25,000
0.0
%
8
Scott M. Cutler
20,000
20,000
0.0
%
9
Joann R. DeSheplo
20,000
20,000
0.0
%
10
Wayne Miller
10,000
10,000
0.0
%
11
Kathleen Muhlmeister
25,000
25,000
0.0
%
12
First Time II LLC
400,000
400,000
0.0
%
11
PLAN OF DISTRIBUTION
Summary
We have agreed to register for public resale our common shares, which have been issued to the
selling shareholders. This offering will terminate on the earlier of (i) the date on which the
shares may be resold by the selling stockholders without registration and without regard to any
volume limitations by reason of Rule 144 under the Securities Act or any other rule of similar
effect or (ii) all of the shares have been sold pursuant to this prospectus of Rule 144 under the
Securities Act or any other rule of similar effect. The selling shareholders will receive all of
the net proceeds from their sales. Prior to having the shares quoted on OTCBB, the selling
shareholders may, from time to time, sell all or a portion of the shares of common stock of our
Company, which they own at $0.50 per share. After the shares of the Company are quoted for trading
on the OTCBB, the selling shareholders may sell their shares at the then market prices on the OTCBB
or privately negotiated prices, which may be less than or greater than $0.50 per share. Presently,
the selling shareholders cannot sell their common stock of our company except in accordance with
new Rule 144 under the Securities Act because we are defined as a "shell company."
The selling shareholders may sell their shares of common stock of our company directly to
purchasers or may use brokers, dealers, underwriters or agents to sell such Shares. Brokers or
dealers may receive commissions, discounts or concessions from a selling shareholder or, if any
such broker or dealer acts as agent for the purchaser of such shares, from a purchaser in amounts
to be negotiated. Such compensation may, but is not expected to, exceed that which is customary
for the types of transactions involved.
The selling shareholders and any brokers, dealers or agents that participate with the selling
shareholders in sales of their shares or common stock of our Company may be deemed to be
"underwriters' within the meaning of the Securities Act of 1933 in connection with such sales. In
such event, any commissions received by such brokers, dealers or agents and any profit on the
resale of such shares purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act of 1933.
We are required to pay all fees and expenses incident to the registration of our shares of common
stock offered hereby other than broker or dealer discounts and commissions.
The officers and directors of HCA have agreed to sell only shares as allowed by the volume
limitations under Rule 144 for the first year that company stock is traded on the OTCBB.
12
SELLING SHAREHOLDER'S "UNDERWRITER" STATUS: PROSPECTUS DELIVERY REQUIREMENT
Shareholders of the Company who resell their securities pursuant to this prospectus may be deemed
to be statutory "underwriters" (as defined in Securities Act of 1933 Section 2(11)) and "engaged in
a public distribution." Accordingly, HCA intends to deliver a prospectus to each shareholder.
Each selling shareholder should review it carefully and deliver it to any broker or dealer engaged
to sell stock or to any buyer in a direct sale. Selling shareholders and certain brokers and
dealers are required to deliver a prospectus 48 hours prior to confirming sales. Additional copies
of the prospectus may be printed by accessing it on the SEC website at http:\www.sec.gov, or it may
be obtained by writing or calling Healthcare Corporation of America, 36 Kevin Drive, Flanders, New
Jersey 07836, telephone 973 796 4216. See "Selling shareholders" above for information as to the
largest shareholders, the amounts owned, and any relationships with HCA.
Suggested Selling Shareholder's Underwriting Compliance Procedures
Except as indicated under "Selling Shareholders" none of the shareholders is known to HCA to be a
broker-dealer or affiliates of broker-dealers or to have any experience in the distribution of
securities or to have any material relationships with HCA. HCA is not aware of any intent by a
shareholder to engage in passive market making transactions as permitted by Rule 10b-6A under the
Securities Exchange Act of 1934 or in stabilization or other transactions affecting the market
price. We are not aware of any intent by our officers, directors or principal shareholders to
purchase shares from selling shareholders.
It is suggested to selling shareholders that, to avoid technical violations of underwriting
regulations, they should observe the prospectus delivery requirement described herein and also
consult with their legal counsel. These suggestions do not constitute legal advice or any
representation or warranty that these are necessary or sufficient to comply with or avoid
enforcement action (civil or criminal) for alleged violations of any type of law. Shareholders
engaging in any direct or indirect transactions of any nature as to any of HCA's securities do so
at their own risk and expense. All sales should be conducted through brokers or dealers, who
should be given a copy of the prospectus and advised of the SEC and NASD position that such sales
may be deemed to be part of a "public distribution" by statutory "underwriters" (selling
shareholders). No purchases of shares or other transactions having the purpose or effect of
affecting the price should be engaged in my or on behalf of shareholders before or after the sale.
HCA's public reporting status should be brought to the brokers' or dealers' attention. Updated
information about HCA will be in the reports to the SEC at
13
http:\www.sec.gov. See "Available Information" near the end of the prospectus for further details
on how to obtain copies of such reports.
Although isolated resales often are exempt from state "blue sky" securities regulation and
registration requirements and the reporting company status of an issuer broadens the availability
of resale exemptions, selling shareholders should be cautious in view of their "underwriter" status
in the eyes of the SEC and NASD. They are urged to consult qualified local securities counsel.
HCA is not undertaking, and it will be the selling shareholders' responsibility, to file any
necessary state exemption, qualification, or registration statements or notices (such as Form U-1)
and offering documents (such as this prospectus) if needed for resales in a particular state.
The selling shareholders may offer their shares of common stock at various times in one or more of
the following transactions:
•
In the over-the-counter market;
•
In private transactions other than in the over-the-counter market;
•
In connection with short sales of our shares;
•
By pledge to secure debts and other obligations; or
•
In a combination of any of the above transactions.
The selling shareholders may sell their shares at market prices prevailing at the time of the sale,
at prices related to such prevailing market prices, at negotiated prices or fixed prices. Until
the shares of the Company are quoted for trading on the OTCBB, the selling shareholders will sell
their shares at a price of $0.50 per share. After the shares of the Company are quoted for trading
on the OTCBB, the selling shareholders may sell their shares at the then market price on the OTCBB
or privately negotiated prices, which may be less than or greater than $0.50 per share.
The selling shareholders may use brokers or dealers to sell their shares. Sales through brokers of
dealers may involve one or more of the following;
•
Block trades in which the broker or dealer so engaged will attempt to sell the selling
shareholder's shares as agent but may position and resell a portion of the block as
principal to facilitate the transaction;
•
Purchases by a broker or dealer as principal and resale by such broker or dealer for its
own account pursuant to this prospectus; or
14
•
Ordinary brokerage transactions and transactions in which the broker solicits
purchasers.
If a broker or dealer is engaged by a selling shareholder, such broker or dealer may either receive
discounts or commissions from the selling shareholders, or they will receive commissions from
purchasers of shares for whom they acted as agents. Affiliates of one or more of the selling
shareholders may act as principals or agents in connection with the offer or sale of shares by
selling shareholders.
Selling shareholders also may resell all or a portion of the shares in open market transactions in
reliance upon Rule 144 under the Securities Act of 1933, as amended, provided that they meet the
criteria and conform to the requirements of that Rule.
Selling shareholders have been advised that during the time each is engaged in distribution of the
securities covered by this prospectus, to the extent applicable, each must comply with Regulation M
under the Securities Exchange Act of 1934, as amended, and pursuant to such Regulation:
•
Shall not engage in any stabilization activity in connection with our securities;
•
Shall furnish each broker through which securities covered by this prospectus may be
offered the number of copies of this prospectus which are required by each broker; and
•
Shall not bid for or purchase any of our securities or attempt to induce any person to
purchase any of our securities other than as permitted under the Securities Exchange Act of
1934, as amended.
The selling shareholders and any brokers, dealers or agents that participate with the selling
shareholder in sales of the shares may be deemed to be underwriters within the meaning of the
Securities Act in connection with such sales and subject to any liabilities under such Act. Any
commissions received by such brokers, dealers or agents and any profit on the resale of the shares
purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act.
LEGAL PROCEEDINGS
We are not currently a party to, nor are any of our property currently the subject of, any pending
legal proceeding. None of our directors, officers or affiliates is involved in a proceeding
adverse to our business or has a material interest adverse to our business.
15
Our agent for service of process is Joseph Drucker, Attorney at Law, 43 Sawgrass Street, Jackson,
New Jersey 08520.
DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS
The following table sets forth the directors and executive officers of our company, their ages,
term served and all officers and positions with our Company. Pursuant to our bylaws, our directors
are elected at our annual meeting of stockholders and each director holds office until the
successor is elected and qualified. Officers are appointed by our Board of Directors and hold
office until an officer's successor has been duly appointed and qualified unless an officer sooner
dies, resigns or is removed by the Board.
There are no arrangements or understandings regarding the length of time a director of our company
is to serve in such a capacity.
Name
Age
Position
Gary Sekulski
61
Director, President and CEO
Joseph Drucker
87
Director, Secretary, Corporate Counsel
Jan Goldberg
57
Executive Vice President, Administration
Set forth below is a brief description of the background and business experience of our current
executive officers and directors:
Gary J. Sekulski – CEO, President and Director
Mr. Sekulski is an experienced executive with a primary focus on business development and the
development of products and services to effectively address operational and marketing challenges in
the healthcare and prescription drug market sectors. Mr. Sekulski was a Founder and President of
Broadreach Medical Resources where he created a new more cost effective business model for
administrating prescription drug programs using transparency and full disclosure business
practices. He was President of the Gladstone Consulting Group, a healthcare product development,
medical underwriting and project management company that developed innovative products in chronic
illness management, prescription drugs and dental. Over the years, Mr. Sekulski has held various
executive positions with organizations such as Executive Vice President at Summit Health
Administrators, an organization that processed the professional claims for HIP of New York
servicing HIP's 1.2 million members, and Senior Vice President of Product Development at Medco
Containment Services (now Medco Health Solutions), where he was instrumental in developing mail
service plans, integrated walk-in card/mail service plans, managed care pharmacy networks,
formulary/ rebate programs and the marketing strategies to implement these programs. Prior to
this, Mr. Sekulski had been the National Director of Metropolitan Life Insurance Company's provider
network programs including prescription drugs
16
(GM, Goodyear, GE), vision (created Bell Company and AT&T original program) and dental (formulated
first national network). In this capacity, claims operations with over 750 employees reported to
Mr. Sekulski. While at Metropolitan, Mr. Sekulski also supervised Metropolitan's Internal Medical
Underwriting Division. Mr. Sekulski has served on the 1985 General Motors/UAW Benefits Cost
Containment Task Force; the Medicare Catastrophic Prescription Drug Act Committee; Chair of the
HIAA Pharmaceutical Relations Committee; Chair of the By-laws Committee-National Council of
Prescription Drug Programs. He has also been a member of the Self-Insurance Institute of America,
and the National Association of Chain Drug Stores. Mr. Sekulski is a graduate of Stony Brook
University.
Jan Goldberg-Executive Vice President -Administration
Mr. Goldberg has a proven record of improving operations and unit performance while reducing costs
in the challenging health care environment. He has managed complex multiple sites and large
operations, negotiated mergers and acquisitions, labor contracts and business contracts. Mr.
Goldberg's diverse career has included Senior Vice President of Facility Operations for Integrated
Medical LLC, a medical and Real Estate Management Company; Principle, Founder and Executive Vice
President of Modern Medical Modalities Corporation, a multi state diagnostic imaging company;
Founder and President of CSB Billing and Management Inc., a physician billing company located in
Florida. He has also served as Director of Operations for Advacare, Inc. a national billing and
Management Company and as New Jersey Director of Operations for Sonix Medical Resources. Early in
his career he has served in the finance departments of Booth Memorial Medical Center and Staten
Island University Medical Center. He started his career with Blue Cross/ Blue Shield of Greater New
York. Mr. Goldberg is a graduate of Pace University.
Joseph Drucker-Corporate Counsel, Secretary and Director
Mr. Drucker, Esq., manages HCA's Legal Department and Legal affairs which will include overseeing
HCA's filings with the Securities and Exchange Commission. Mr. Drucker has had a distinguished
career from 1946 to date serving as a Director and Officer of both Private and Public Corporations.
From 1983 to 1997, Mr. Drucker served as Co-Chairman, Secretary and General Counsel of a small cap
public Company. Mr. Drucker has been in the private practice of law since 1973. He was a partner
in the law firm of Himmelman, Hurley, Drucker and Himmelman. As an attorney, Mr. Drucker limits
his practice to corporate law and specializes in the formation of business plans, Private Placement
Memoranda and the filing of registration statements with the Securities and Exchange Commission to
authorize the sale of Company's securities to public investors and reverse mergers. Mr. Drucker's
diverse career also included being a managing partner of the accounting firm of Reimer, Drucker,
Biegeleisen and Standard located in Freehold, New Jersey. Mr. Drucker Attended Columbia University
and received a B.S. Degree in Business and Accounting from Long Island University and a Juris
Doctorate Degree from Brooklyn Law School.
17
Summary Annual Compensation Table
Compensation-
October 1, 2008
($) Number of shares
Name and Principal Position
($) Salary
($) Bonus
Underlying Options (#)
Gary Sekulski, CEO
$
360,000
NONE
NONE
Joseph Drucker, Secy
$
120,000
NONE
NONE
Jan Goldberg, Exec VP
$
180,000
NONE
NONE
See financial statements Note 3, Executive Compensation (accrued salaries).
18
Director Compensation Table
Fees Earned or
Stock Awards of
Paid in Cash
Options
All other Compensation
Name
($)
($)
($)
Gary Sekulski
NONE
NONE
NONE
Joseph Drucker
NONE
NONE
NONE
Note: Board of Directors will determine if bonus payments will be made at end of fiscal year based
on financial position. Board of Directors may also determine if fees will be paid to Directors.
We do not presently have a stock option plan but intend to develop an incentive based stock option
plan for our officers and directors in the future and may reserve a percentage of our outstanding
shares of common stock for that purpose.
COMMITTEES OF THE BOARD OF DIRECTORS
The functions of the audit committee are currently carried out by our Board of Directors. We do
not have a financial expert on our Board. Our Board has determined that we do not need such an
expert. The cost of hiring a financial expert to act as a director of HCA and to be a member of
the audit committee or otherwise perform audit committee functions outweighs the benefits of joromg
a financial expert on the audit committee. We do not have a compensation committee, nominating
committee, an executive committee on our board of directors, stock plan committee or any other
committees.
INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS
None of our directors, executive officers, promoters or control persons has been involved in any of
the following events during the past five years:
•
any bankruptcy petition filed by or against any business of which such person was a
general partner or executive officer either at the time of the bankruptcy or within two
years prior to that time;
•
any conviction in a criminal proceeding or being subject to a pending criminal
proceeding (excluding traffic violations and other minor offences);
•
being subject to any order, judgment or decree, not subsequently reversed, suspended or
vacated of any court of competent jurisdiction, permanently or
19
temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type
of business, securities or banking activities; or
•
found by a court of competent jurisdiction (in a civil action ), the Commission or the
Commodity Futures Trading Commission to have violated a federal or state securities or
commodities law, and the judgment has not been reversed, suspended, or vacated.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information as of December 31, 2008, with respect to the
beneficial ownership of our company's common stock with respect to each named director and
executive officer of our Company, each person known to our company to be the beneficial owner of
more than five percent (5%) of said securities, and all directors and executive officers of our
Company as a group. Unless otherwise indicated, the address for each listed person is c/o
Healthcare Corporation of America, 36 Kevin Drive, Flanders, New Jersey 07836.
Amount and Nature
of Beneficial
Percentage
Name and Address
Title of Class
Ownership
of Class
Gary Sekulski
Common
9,500,000
69.9
President, CEO and Director
Joseph Drucker
Common
3,000,000
22.0
Secretary and Director
JanGoldberg
Common
500,000
3.7
Vice President administration
(1)
The percentage of class is based on 13,630,000 shares of common stock issued and outstanding
as of the date hereof.
The persons named above have full voting and investment power with respect to the shares indicated.
Under the rules of the Securities and Exchange Commission, a person (or group of persons) is
deemed to be a "beneficial owner" of a security if he or she, directly or indirectly, has or shares
the power to vote or to direct the voting of such security, or the power to dispose of or to direct
the disposition of such security. Accordingly, more than one person may be deemed to be a
beneficial owner of the same security. A person is also deemed to be a beneficial owner of any
security which that
20
person has the right to acquire within 60 days, such as options or warrants to purchase our common
stock.
DESCRIPTION OF CAPITAL STOCK
The shares registered pursuant to this registration statement are shares of common stock, all of
the same class and entitled to the same rights and privileges as all other shares of common stock.
Common Stock
HCA is presently authorized to issue 25,000,000 shares of common stock, no par value per share. As
of the date hereof, there were 13,630,000 shares of our common stock issued and outstanding, held
by 12 stockholders of record.
Our common stock is entitled to one vote per share on all matters submitted to a vote of the
stockholders, including the election of directors. Except as otherwise required by law or provided
in any resolution adopted by our board of directors with respect to any series of preferred stock,
the holders of our common stock will possess all voting power. Generally, all matters to be voted
on by stockholders must be approved by a majority (or in the case of selection of directors, by a
plurality) of the votes entitled to be cast by all shares of our common stock that are present in
person or represented by proxy, subject to any voting rights granted to holders of any preferred
stock. Holders of our common stock representing ten-percent (10%) of our capital stock issued,
outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a
quorum at any meeting of our stockholders. A vote by the holders of a majority of our outstanding
shares is required to effectuate certain fundamental corporate changes such as liquidation, merger
or an amendment to our Articles of Incorporation. Our Articles of Incorporation do not provide for
cumulative voting in the election of directors.
Subject to any preferential rights of any outstanding series of preferred stock created by our
board of directors from time to time, the holders of shares of our common stock will be entitled to
such cash dividends as may be declared from time to time by our board of directors from funds
available therefore. See "Dividend Policy."
Subject to any preferential rights of any outstanding series of preferred stock created from time
to time by our board directors, upon liquidation, dissolution or winding up of HCA, the holders of
shares of our common stock will be entitled to receive pro rata all assets of HCA available for
distribution to such holders.
21
In the event of any merger or consolidation of our company with or into another company in
connection with which shares of our common stock are converted into or exchangeable for shares of
stock, other securities or property (including cash), all holders of our common stock will be
entitled to receive the same kind and amount of shares of stock and other securities and property
(including cash).
Holders of our common stock have no pre-emptive rights, no conversion rights and there are no
redemption provisions applicable to our common stock.
Preferred Stock
As of the date hereof, HCA has no preferred stock authorized or issued.
DIVIDEND POLICY
We have never declared or paid any cash dividends on our common stock. We currently intend to
retain future earnings, if any, to finance the expansion of our business. As a result, we do not
anticipate paying any cash dividends in the foreseeable future.
Share Purchase Warrants
We have not issued and do not have outstanding any warrants to purchase shares of our common stock.
Options
We have not issued and do not have outstanding any options to purchase shares of our common stock.
Convertible Securities
We have not issued and do not have outstanding any convertible into shares of our common stock or
any rights convertible or exchangeable into shares of our common stock.
LEGAL MATTERS
Joseph Drucker has provided an opinion of the validity of our common stock offered by the Selling
Shareholders.
22
Experts
Moore Associates, ("Chartered Accountants"), our independent registered public accounting firm, has
audited our financial statements included in this prospectus and registration statement to the
extent and for the period set forth in their audit report. Moore Associates has presented their
report with respect to our audited financial statements. The report of Moore Associates is
included in reliance upon their authority as experts in accounting and auditing.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
There have not been any changes in or disagreements with our accountants on accounting and
financial disclosure or any other matter.
MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
No Public Market for Common Stock
There is presently no public market for our common stock. We anticipate making an application for
trading of our common stock on the OTCBB upon the effectiveness of this registration statement of
which the prospectus forms a part. We are qualifying for resale up to 13,630,000 common shares
pursuant to this registration statement. However, we can provide no assurance that our shares will
be traded on the bulletin board or, if traded, that a public market will materialize.
New Rule 144
HCA is presently a "shell company" as defined under rule 405 of the Securities Act and Rule 12b-2
of the Exchange Act. Effective February 15, 2008, the SEC amended Rule 144 of the Securities Act
of 1933, which do not allow shareholders to rely on Rule 144 for the resale of securities of a
shell company. Shareholders may only rely on new Rule 144 if HCA ceases to be a shell company and
only if all of the following conditions are met: the issuer has ceased to be a shell company; the
issuer is subject to the reporting requirements of the Exchange Act; the issuer has filed all
Exchange Act reports required for the past 12 months; and at least one year has elapsed from the
time that the issuer filed current Form 10 information on Form 8-K changing the status to a
non-shell company.
23
If HCA is
defined as not a "shell company," a total of 13,630,000 shares of our restricted common
stock will be available for resale to the public, in accordance with the volume and trading
limitations of new Rule 144. Also pursuant to the amended provision of Rule 144, following the
six-month holding period but before one year after their acquisition of the securities, a person
who is not an affiliate and has not been an affiliate for at least three months prior to the sale,
will be able to make unlimited public resales under Rule 144 except that the current public
information requirement will still apply. After the one-year holding period, such non-affiliates
may make unlimited public resales under rule 144 and need not comply with any other rule 144
requirements.
The one year and six month holding periods described above do not begin to run until the full
purchase price or other consideration is paid by the person acquiring the shares from the issuer or
an affiliate. However, we are a "shell company" and shareholders holding restricted stock cannot
rely on Rule 144 to resell their restricted shares.
Penny Stock Regulation
Our shares will have to comply with the Penny Stock Reform Act of 1990, which may potentially
decrease your ability to easily transfer our shares. Broker-dealer practices in connection with
transactions in "penny Stocks" are regulated. Penny stocks generally are equity securities with a
price of less than $5.00. the penny stock rules require a broker-dealer, prior to a transaction in
a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure
document that provides information about penny stocks and the risks in the penny stock market. The
broker-dealer also must provide the customer with current bid and other quotations for the penny
stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly
account statements showing the market value of each penny stock held in the customer's account. In
addition, the penny stock rules generally require that prior to a transaction in a penny stock, the
broker-dealer make a special written determination that the penny stock is a suitable investment
for the purchaser and receive the purchaser's written agreement to the transaction. These
disclosure requirements may have the effect of reducing the level of trading activity in the
secondary market for a stock that has to comply with the penny stock rules. As our shares
immediately following this offering will likely have to comply with such penny stock rules,
investors in this offering will in all likelihood find it more difficult to sell their securities.
EXPERTS
The financial statements included in this prospectus have been audited by Moore & Associates,
Chartered Public Accountants. Reference is made to the auditor's report. These financial
statements are furnished in reliance upon the auditor's report.
24
INDEMNIFICATION
New Jersey corporate law provides that a corporation may indemnify any person who was or is a
party, or is threatened to be made a party, to any threatened, pending or completed action, suit or
proceeding whether civil, criminal administrative or investigative, except an action by or in the
right of the corporation, by reason of the fact that he is or was a director, officer, employee or
agent of the corporation, or is or was serving at the request of the corporation as director,
officer, employee or agent of another corporation, partnership, joint venture, trust of other
enterprise, against expenses, including attorneys' fees, judgments, fines and amounts paid in
settlement actually and reasonably incurred by him in connection with the action, suit or
proceeding if he acted in good faith and in a manner which he reasonable believed to be in or not
opposed to the best interests of the corporation, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe his conduct was unlawful.
New Jersey corporate law also provides that, to the extent that a director, officer, employee or
agent of a corporation has been successful on the merits or otherwise in defense of any action,
suit or proceeding, or in defense of any claim, issue or matter therein, the corporation shall
indemnify him against expenses, including attorneys' fees, actually and reasonably incurred by him
in connection with the defense.
Our Articles of Incorporation and By-Laws limit the liability of our directors, officers, agents,
fiduciaries and employees to the fullest extent permitted by the New Jersey Revised Statutes.
Specifically, directors of the company will not be personally liable to the Company or any of its
shareholders for monetary damages for breach of fiduciary duty as directors, except liability for:
(i) any breach of the director's duty of loyalty to the corporation or its shareholders; (ii) acts
or omissions not in good faith or which involve intentional misconduct or a knowing violation of
law; (iii) voting for or assenting to a distribution in violation of New Jersey law; or (iv) any
transaction from which the director directly or indirectly derives an improper personal benefit.
Our governing documents therefore protect officers, directors, agents, fiduciaries, and employees
to the fullest extent permissible under New Jersey law.
DISCLOSURES OF COMMISSION'S POSITION ON INDEMNIFICATION
OF SECURITIES ACT LIABILITIES
We have been advised that in the opinion of the Securities and Exchange Commission indemnification
for liabilities arising under the Securities Act of 1933, as amended, is against public policy as
expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities is asserted by one of
25
our directors, officers, or
controlling persons in connection with the securities being registered, we will either rely upon
the opinion of counsel as to whether or not to pay indemnification, or submit the matter to a court
of appropriate jurisdiction.
Dividends
No dividends have been declared on the common shares as of the date hereof and the Company has no
plans to declare dividends in the near future.
Disclosures of Commission Position on Indemnification for Securities Act Liabilities
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
directors, officers and controlling persons of the registrant pursuant to the foregoing provisions,
or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or controlling person of the
registrant in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court or appropriate jurisdiction the question whether such indemnification
bi it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issues.
The foregoing right of indemnification shall not be deemed exclusive of any rights to which any
officer or director or employee may be entitled apart from the provisions of this section.
The amount of indemnity to which any officer or any director may be entitled shall be fixed by the
Board of Directors, except that in any case where there is not disinterested majority of the Board
available, the amount shall be fixed by arbitration pursuant to the then existing rules of the
American Arbitration Association.
Transactions with Related Persons
On March 10, 2008, we issued 13,000,000 shares of our common stock to Gary Sekulski, Joseph Drucker
and Jan Goldberg, our directors and officers, at $.0001 per share and aggregate proceeds of $1300.
Reports to Security Holders
26
We intend to furnish our stockholders annual reports containing audited financial statements.
The financial statements included in this prospectus have been audited by Moore & Associates,
Chartered Accountants. Reference is made to the auditor's report. These financial statements are
furnished in reliance upon the auditor's report.
AVAILABLE INFORMATION
We have filed with the SEC a registration statement on Form S-1 to cover the securities to be sold
hereunder. This prospectus forms a part of that registration statement, and the registration
statement also includes certain exhibits. This prospectus therefore does not contain all of the
information set forth in the registration statement and exhibits to the registration statement.
For further information with respect to our company and the shares of common stock to be sold in
this offering, reference is made to the registration statement, including the exhibits to the
registration statement. Copies of the registration statement, including the exhibits to the
registration statement, may be examined without charge ad the public reference room of the SEC, 100
F Street, N.W., Room 1580, Washington, DC 20549. Information about the operation of the public
reference room may be obtained by calling the SEC at 1-800-SEC-0330. Copies of all or a portion of
the registration statement may be obtained from the public reference room of the SEC upon payment
of prescribed fees. Our SEC filings, including our registration statement, are also available to
you on the SEC's website at
www.sec.gov
.
As a result of this offering, we will become subject to the informational and reporting
requirements of the Securities Exchange Act, and will file periodic reports, proxy statements and
will make available to our stockholders annual reports containing audited financial information for
each year and quarterly reports for the first three quarters of each fiscal year containing
unaudited interim financial information.
BUSINESS
INTRODUCTION
GENERAL
Healthcare Corporation of America
Any estimates and projections contained herein have been prepared by management of the company and
involve significant elements of subjective judgment and analysis.
27
EXECUTIVE SUMMARY
Healthcare Corporation of America
Background
The pharmaceutical market sector is the most profitable of all U.S. industries based on revenue,
equity and assets according to Fortune Magazine. Within this sector, the fastest growing and most
profitable component of the medication dispensing process is the "Closed Door Pharmacy" (a pharmacy
that does not service the general public). At the present time, Closed Door Pharmacies include Long
Term Care (nursing homes and assisted living facilities) Mail Order, Specialty Pharmacy, and
Central Fill Pharmacy (funded prescription drug programs).
Corporate Organization
HCA is a
New Jersey Corporation that was formed February 26, 2008. At the present time, HCA is a
Product Development and Marketing Company that has developed a new business model that will reduce
and control pharmacy costs for non-profit organizations through a product offering that utilizes
the Closed Door Pharmacy concept in a new and unique way. For its pharmacy ventures, HCA has
formed, Prescription Corporation of America (PCA), a wholly owned subsidiary. In order to provide
dispensing pharmacy services, PCA has entered into participating pharmacy agreements with Kings
Pharmacy, Newark, New Jersey, Jacobs Pharmacy, Paterson, New Jersey and Fountain Hill Pharmacy in
Bethlehem, Pennsylvania. HCA plans to add pharmacies to service clients in new geographic locations
as the demand for its product grows and to open HCA's own pharmacy in the future.
HCA has also entered into discussions with Standard Security Life Insurance to form a reinsurance
underwriting facility (a planned HCA subsidiary for the First Quarter 2009) in order to guarantee
the lower program costs achieved by PCA programs to plan sponsors through an Aggregate Stop Loss
Policy. In the future, HCA plans to add a Pharmacy Benefit Manager (PBM) subsidiary which will
service prescription drug programs, thereby, complementing HCA's two other subsidiaries and which
will add a third source of revenue.
As part of its business strategy, HCA plans to become a public company. Currently, HCA is seeking
up to $1 million in funding through a Private Placement Memorandum at $.50 per share to accelerate
its growth rate. HCA is a non-trading Company with 25 million authorized shares of common stock.
Our intention is to file this S-1
28
Registration, through a market maker file a 15c211 and become a public company trading on the
OTCBB.
Operations
PCA's pharmacies house both Unit Dose (packaging of medications by Bingo Punch Cards, Unit Dose
Boxes or PAC Med Pouches) and Vial (packaging of medications into patient specific containers) Base
dispensing capabilities in one Closed Door Pharmacy. This gives PCA access to the long term care
and funded prescription drug program market sectors as a Long Term Care Pharmacy, Mail Order
Pharmacy and Central Fill Pharmacy. While each of these pharmacies service different end
recipients, there is commonality in staff, particularly among pharmacists, administrative functions
and purchasing practices. As part of the plan, HCA will centralize corporate staff, sales and
marketing, pharmaceutical purchasing and redundant administrative functions in one location. It is
anticipated that this structure will add margin because of the improved overall cost effectiveness
of the Company and due to the improvement in purchasing practices of medications with the
consolidation of volume.
Marketing Strategy
With this multiple pharmacy capability, HCA is focusing on the non-profit market sector which
includes school districts, charitable organizations, hospitals, colleges, non-profit long term care
facilities and universities. HCA has worked closely with the Federal Trade Commission and has
received several favorable rulings from governmental agencies that permit PCA to improve purchasing
practices and pricing for these non-profit entities. This has become a significant competitive
advantage for HCA.
HCA has also been approached by several Home Health Care Agencies to have PCA could formulate a
solution to the administration of medication to home patients being serviced by these agencies.
Currently, to comply with laws, Nurses must transfer medications from vials obtained at the
patient's pharmacy to daily dose 30 day bingo cards so that care givers can distribute medications
to patients. In response to this demand, PCA has formulated a new pharmacy product for this market
sector which solves the medication administration problems for home care agencies at a reduce cost
to the home care patients these agencies service by using unit dose pouch packaging with direct
home delivery.
In order to promote the fastest distribution of product in the market, HCA has decided to
compliment its internal sales efforts and has contracted with or is in the process of contracting
with several major sales distribution systems that present multiple immediate business
opportunities. These organizations include the Colonial
29
Consulting Group; Willis HRH, a top 10 national insurance broker employee benefit consultant;
independent sales agents, John Wohtowicz and AXA Financial Group.
Current Status
PCA launched its Non-Profit Pharmacy Program in the fall of 2008. PCA is implementing its first
group of clients effective Second Quarter 2009. These include School Districts in Fort Lee, Phillipsburg, and
Toms River. In addition, PCA is adding the Fort Lee Senior Center. This encompasses approximately 10,000 family units (a family unit is the
combination of employee, employee plus spouse, employee plus children
and families)*. PCA also has a contractual commitment** from to place 10,000 family units on the non-profit program by
July 2009. In addition, PCA is in active discussions with Bergen County Schools, Edison,
Woodbridge, Jackson, Berkley and Manchester. PCA is also
directly pursuing Englewood, Passaic, Palisades Park, and Cliffside Park. The number of family units for these two groups exceeds 20,000 family units***. In
addition, while still in early discussion stages, PCA has had
preliminary discussions with the Attorney for the Maryland School
System and the Pennsylvania (900,000 family units) and Maryland
AFL-CIO with 125,000 family units****.
As part of its non-profit program, PCA has contracted with Palisades Medical Center and is
currently pursuing business relationships with Kimball Medical Center in Lakewood, New Jersey; Englewood Hospital; Raritan
Bay in Old Bridge; Westfield Hospital in Allentown, Pennsylvania and
Doylestown Medical Center. These organizations currently
generate over 150,000 prescriptions per year*****.
Lastly, Caring People, a five state home care agency, has approached PCA concerning using its
Medicine on Time PACMed Pouch for the approximate 1,000 patients it currently services. We
estimate that this would constitute approximately 60,000 to 80,000 prescriptions per year******.
Footnotes: *Group1; **Group 2; ***Group 3; ****Group 4; *****Group 5; and ******Group 6.
Financial Projections-Annualized First Year
Family
Annual
Annual
Gross
Group
Units
Prescriptions
Sales
Profit
EBITA
1
10,000
90,000
$
9,000,000
$
1,350,000
$
450,000
2
10,000
90,000
$
9,000,000
$
1,350,000
$
450,000
3
20,000
180,000
$
18,000,000
$
2,700,000
$
900,000
30
Family
Annual
Annual
Gross
Group
Units
Prescriptions
Sales
Profit
EBITA
4*
62,500
562,500
$
56,250,000
$
8,437,500
$
2,812,500
5
5,000
150,000
$
15,000,000
$
2,250,000
$
750,000
6
1,000
70,000
$
7,000,000
$
1,050,000
$
350,000
Total
108,500
1,142,500
$
114,250,000
$
17,137,500
$
5,712,500
*
Assume 50% sales success rate.
Assumptions:30 Rxs per family unit; $100 per Rx; $15 Gross Profit per Rx; and $6 EBITA per
prescription.
STOCK ISSUANCES
The Company was incorporated February 26, 2008. Total authorized shares: 25,000,000. As of
December 31, 2009, the Board of Directors approved a total of 13,630,000 shares issued and
outstanding.
Chief Executive Officer and President, Gary Sekulski, 9,500,000 shares.
Joseph Drucker, Corporate Counsel, Secretary and Chief Financial Officer, 3,000,000 shares.
Jan Goldberg, Executive Vice President,500,000 shares.
Matilda Bruno, Consultant,50,000 shares.
Steve Monetti, Consultant, 20,000 shares.
Wayne Miller, Consultant, 10,000 shares.
Scott M. Cutler purchased 20,000 shares for $10,000 as an accredited investor from the Form
D Reg 504 Private Placement Memorandum.
John R. DeSheplo purchased 20,000 shares for $10,000 as an accredited investor from the Form D
Reg 504 Private Placement Memorandum.
Buy Sell Pharmacy.com, Consultant, 25,000 shares.
31
Colonial Consulting Group LLC, Consultant, 60,000 shares.
Kathleen and Keith Muhlmeister, accredited investors from the Form D Reg 504 Private
Placement Memorandum, 25,000 shares.
First Time LLC Stock Purchase Agreement, 400,000 shares.
32
DESCRIPTION OF SECURITIES
The following statements are qualified in their entirety by reference to the detailed provisions of
our Certificate of Incorporation, as amended, and By-Laws. The Shares registered pursuant to the
registration statement of which this Prospectus is a part are shares of common stock, all of the
same class and entitled to the same rights and privileges as all other shares of common stock.
Capital Stock
The authorized capital stock of the Company is 25,000,000 shares of common stock, with no par value
per share.
As of the date of this prospectus, there are 13,630,000 shares of common stock issued outstanding.
There is no preferred stock authorized.
Options and Warrants
There are no outstanding options or warrants or other securities that are convertible into our
common stock.
Voting Rights
Each shareholder is entitled to one (1) vote for each share of voting stock.
Dividend Policy
We intend to retain and use any future earnings for the development and expansion of our business
and do not anticipate paying any cash dividends in the foreseeable future.
Transfer Agent
The registrar and transfer agent for our common stock is Corporate Stock Transfer Inc., 3200 Cherry
Creek Drive South, Suite 430, Denver, CO 80109.
Penny Stock Regulation
The SEC has adopted regulations which generally define "penny stock" to be any equity security that
has a market price (as defined) of less than $5.00 per share or an exercise price of less than
$5.00 per share. Such securities are subject to rules that impose additional sales practice
requirements on broker-dealers who sell them. For transactions covered by these rules, the
broker-dealer must make a special suitability
33
determination for the purchaser of such securities and have received the purchaser's written
consent to the transaction prior to the purchase. Additionally, for any transaction involving a
penny stock, unless exempt, the rules require the delivery, prior to the transaction, of a
disclosure schedule prepared by the SEC relating to the penny stock market. The broker-dealer also
must disclose the commissions payable to both the broker-dealer and the registered representative,
current quotations for the securities and, if the broker-dealer is the sole market-maker, the
broker-dealer must disclose this fact and the broker-dealer's presumed control over the market.
Finally, among other requirements, monthly statements must be sent disclosing recent price
information for the penny stock held in the account and information on the limited market in penny
stocks. As the Shares immediately following this Offering will likely be subject to such penny
stock rules, purchasers in this Offering will in all likelihood find it more difficult to sell
their Shares in the secondary market.
The financial statements of the Company as of December 31, 2008 and for the period from February
26, 2008 (inception) through December 31, 2008, included in this Registration Statement have been
audited by Moore & Associates Chartered Accountants, 6490 West Desert Inn Road, Las Vegas,
NV 89146, tel. 702 253 7499, and have been so included in reliance upon the report of Moore &
Associates Chartered Accountants given on the authority of such firm as experts in accounting and
auditing.
UNDERTAKINGS
The undersigned Registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement;
(i)
To include any prospectus required by Section 10(a)(3) OF THE Securities Act of
1922, as amended;
(ii)
To reflect in the prospectus any facts or events arising after the effective
date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the
information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any deviation from
the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) (§230.424)b) of
this chapter) if, in the aggregate, the changes in volume and price represent no more
than 20% change in the maximum
34
aggregate offering price set forth in the "Calculation of Registration Fee" table in
the effective registration statement;
(iii)
To include any material information with respect to the plan of distribution
not previously disclosed in the registration statements or any material change to such
information in the registration statement;
Provided, however that paragraphs (1)(i), (1)(ii) and (1)(iii) do not apply if the information
required to be included in a post-effective amendment by those paragraphs is contained in periodic
reports filed by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange
Act of 1934 that are incorporated by reference in the registration statement, or is contained in a
form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement;
(2)
That, for the purpose of determining any liability under the Securities Act of
1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the offering.
(4)
Each prospectus filed pursuant to Rule 424(b) as part of a registration
statement relating to an offering, other than registration statements relying on Rule
430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be
part of and included in the registration statement as of the date it is first used
after effectiveness. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a
document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will as to a
purchaser with time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part
of the registration statement or made in any such document immediately prior to such
date of first use.
(5)
For determining liability of the undersigned under the Securities Act to any
purchaser in the initial distribution of the securities, the undersigned undertakes
that in a primary offering of securities of the undersigned pursuant to this
registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by
means of any of the following
35
communications, the undersigned will be a seller to the purchaser and will be
considered to offer or sell such securities to such purchaser:
(i)
Any preliminary prospectus of prospectus of the undersigned small business
issuer relating to the offering required to be filed pursuant to;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf
of the undersigned small business issuer or used or referred to by the undersigned
small business issuer;
(iii)
The portion of any other free writing prospectus relating to the offering
containing material information about the undersigned small business issuer or its
securities provided by or on behalf of the undersigned small business issuer; and
(iv)
Any other communication that is an offer in the offering made by the
undersigned small business issuer to the purchaser.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused
this registration statement to be signed on its behalf by the undersigned, on April 22, 2009.
Healthcare Corporation of America
(Registrant)
By
/s/ Gary
Sekulski
Gary
Sekulski, President,
Chief Executive Officer
Chairman, Board of Directors
Pursuant to the requirements of the Securities Act of 1933, this registration statement has
been signed by the following persons in the capacities and on the dates indicated.
/s/ Gary Sekulski
President, CEO, Chairman of
Board of Directors
(Signature)
(Title)
April 22, 2009
36
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS
, that each person whose signature appears below constitutes and
appoints Patrick C. Brooks and each of them, his true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution for him and in his name, place and stead, in any and
all capacities (including his capacity as a director and/or officer of Healthcare Corporation of
America) to sign any or all amendments (Including post-effective amendments) to this registration
statement and any and all additional registration statements pursuant to rule 462(b) of the
Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other
documents in connection therewith, with the SEC, granting unto each said attorneys-in-fact and
agents, and each of them, full power and authority to do an perform each and every act and thing
requisite and necessary to be done in and about the premises, as fully to all intents and purposes
as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents or any of them, of their or his substitute or substitutes, may lawfully do or cause to
be done by virtue hereof.
In accordance with the requirements of the Securities Act of 1933, as amended, this
registration statement was signed below by the following persons in the capacities and on the dates
stated.
By:
/s/ Gary Sekulski
Gary Sekulski
President, Chief Executive Officer
Chairman, Board of Directors
Dated:
April 20, 2009
37
HEALTHCARE CORPORATION OF AMERICA
and SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2008
HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD FROM INCEPTION ON FEBRUARY 26, 2008 THROUGH
DECEMBER 31, 2008
TABLE OF CONTENTS
Page No.
Report of Independent Registered Public Accounting Firm
1
Consolidated Balance Sheet
2
Consolidated Statement of Operations
3
Consolidated Statement of Cash Flows
4
Consolidated Statement of Stockholders' Equity
5
Notes to Consolidated Financial Statements
6-10
MOORE & ASSOCIATES, CHARTERED
ACCOUNTANTS AND ADVISORS
PCAOB REGISTERED
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors
Healthcare Corporation of America
(A Development Stage Company)
We have audited the accompanying consolidated balance sheet of Healthcare Corporation of America (A
Development Stage Company) as of December 31, 2008 and the related consolidated statements of
operations, stockholders' equity and cash flows for the period from inception on February 26, 2008
through December 31, 2008. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial statements based on our
audits.
We conducted our audits in accordance with standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement. An
audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material
respects, the financial position of Healthcare Corporation of America (A Development Stage Company)
as of December 31, 2008 and the related consolidated statements of operations, stockholders' equity
and cash flows for the period from inception on February 26, 2008 through December 31, 2008, in
conformity with accounting principles generally accepted in the United States of America.
The accompanying consolidated financial statements have been prepared assuming that the Company
will continue as a going concern. As discussed in Note 1 to the financial statements, the Company
is in its development stage, has no established source of revenue, and is dependent on its ability
to raise capital from shareholders or other sources to sustain operations. These factors raise
substantial doubt about its ability to continue as a going concern. Management's plans concerning
these matters are also described in Note 1. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
/s/ Moore & Associates, Chartered
Moore & Associates Chartered
Las Vegas, Nevada
April 16, 2009
6490 West Desert Inn Road, Las Vegas, NV 89146 (702) 253-7499 Fax (702) 253-7501
HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED BALANCE SHEET
December 31, 2008
Assets
Current assets:
Cash
$
14,209
Total current assets
14,209
Total assets
$
14,209
Liabilities and Stockholders' Deficit
Current liabilities:
Accrued expenses
$
79,000
Accrued Officers' Compensation
369,500
Related Party Payables
5,101
Total current liabilities
453,601
Total liabilities
453,601
Stockholders' deficit:
Common stock, no par value,
25,000,000 shares authorized, 13,630,000 shares issued
301,400
Deficit accumulated during the developmental stage
(740,792
)
Total stockholders' deficit
(439,392
)
Total Liabilities and Stockholders' Deficit
$
14,209
See
notes to financial statements.
Page 2
HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED STATEMENT OF OPERATIONS
From inception on
February 26, 2008
through December 31, 2008
Sales
$
—
Cost of sales
—
Gross profit
—
Operating expenses
Officer's salaries
466,300
Consulting fees
137,600
Administrative expenses
14,178
Professional fees
17,000
Total operating expenses
635,078
Loss from Operations
(635,078
)
Write-off of loan balance due from LTC Specialists, LLC
(105,714
)
Provision for Income Tax
—
Net loss
$
(740,792
)
Loss per share
$
(0.06
)
Weighted-average number of common shares outstanding
12,777,330
See
notes to financial statements.
Page 3
HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED STATEMENT OF CASH FLOWS
From inception on
February 26, 2008
through December 31, 2008
Operating activities:
Net loss
$
(740,792
)
Adjustments to reconcile net loss to net cash used in operating activities:
Services paid for with common stock
58,900
Write-off of loan balance due from LTC Specialists, LLC
105,714
Changes in assets and liabilities:
Increase in accrued expenses
79,000
Increase in accrued officers' compensation
369,500
Net cash used in operating activities
(127,678
)
Investing activities:
Increase in loan to LTC Specialists, LLC
(105,714
)
Net cash used in investing activities
(105,714
)
Financing activities:
Increase in Related Party payable
5,101
Increase in stock sold
242,500
Net cash provided by financing activities
247,601
Net increase (decrease) in cash
14,209
Cash at beginning of period
—
Cash at end of period
$
14,209
Cash paid during the period for:
Interest
$
—
Taxes
$
—
Supplemental disclosure of non-cash financing activities:
Stock for Services, Founders shares
$
1,300
Stock for Services, 60,000 shares
$
57,600
See
notes to financial statements.
Page 4
HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
FOR THE PERIOD FROM INCEPTION ON FEBRUARY 26, 2008 THROUGH DECEMBER 31, 2008
Deficit
Accumulated During
Shares
Common Stock
Subscriptions
Development
Total
Issued
Amount
Receivable
Stage
Equity
Founders Shares:
Valued at $0.0001
13,000,000
$
1,300
$
—
$
—
$
1,300
Private Placements:
February 26, 2008 $0.50 per share
20,000
10,000
—
—
10,000
February 29, 2008 $0.50 per share
20,000
10,000
—
—
10,000
February 26, 2008 $0.20 per share
50,000
10,000
—
—
10,000
Shares for Services, 3/31/08:
Colonial Consulting Group, $0.50 per share
60,000
30,000
—
—
30,000
Buy Sell Pharmacy.com, $0.50 per share
25,000
12,500
—
—
12,500
Others, $0.50 per share
30,000
15,100
—
—
15,100
Shares for Expenses Paid 3/31/08
—
—
(42,233
)
—
(42,233
)
Private Placement:
July 3, 2008 $0.50 per share
25,000
12,500
12,500
Stock Issued for cash:
August 28, 2008 $0.50 per share
400,000
200,000
200,000
Services performed for the period ended 12/31/08
42,233
42,233
Net loss
—
—
—
(740,792
)
(740,792
)
Balance,
December 31, 2008
13,630,000
$
301,400
$
—
$
(740,792
)
$
(439,392
)
See notes to financial statements.
Page 5
HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1: Summary of Significant Accounting Policies
Business Activity
Healthcare Corporation of America (HCA) was incorporated in New Jersey on February 26, 2008
with the intent to house institutional pharmacy, mail order pharmacy, and central fill
pharmacy services in one closed pharmacy
Private placements on February 26, 2008 and February 29, 2008, raised a total of $35,000 A
private placement on July 3, 2008 raised a total of $12,500. HCA raised $200,000 on August 28,
2008 through a stock purchase agreement.
The Company is in its development stage. This stage is characterized by significant expenditures
for the design and development of the Company's products and
obtaining financing. Accordingly,
the financial statements are presented in accordance with Statement of Financial Accounting
Standards (SFAS) No. 7
, Accounting and Reporting by
Development-State Enterprises
(SFAS 7).
The accompanying financial statements have been prepared assuming that the company will
continue as a going concern As the company is in its development stage, it has no established
source of revenue and is dependent on its ability to raise capital from shareholders or other
sources to sustain operations. These factors raise substantial doubt that the company will be
able to continue as a going concern. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty
Principles of Consolidation
The consolidated financial statements include the accounts of HCA and its wholly owned
subsidiary, Prescription Corporation of America, which was also formed with the intent to
enter into the pharmaceutical sales industry. All material intercompany accounts and
transactions have been eliminated in consolidation
Cash and Cash Equivalents
Cash and cash equivalents consist of cash on hand and cash in banks, and are stated at cost,
which approximates fair market value. The Company considers all highly liquid debt
instruments with original maturities of three months or less to be cash equivalents.
Accounts Receivable and Allowance for Doubtful Accounts
Trade
accounts receivable are recorded at the invoiced amount and do not bear interest. The
allowance for doubtful accounts is the Company's best estimate of the amount of probable
credit losses in the Company's existing accounts receivable The Company had $0 accounts
receivable at December 31, 2008, and therefore the allowance for doubtful accounts at December
31, 2008 is also $0 Additionally, the Company's bad debt expense for the period ended December 31, 2008 was $0. The Company does not have any off-balance-sheet credit exposure related to
its customers
6
HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1: Summary of Significant Accounting Policies (continued)
Use of Estimates in Preparation of Financial Statements
The preparation of financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and
assumptions that affect the reported amounts of certain assets and liabilities and disclosures of
contingent assets and liabilities at the date of the financial statements and the related reported
amounts of revenues and expenses during the reporting period. Actual results could differ from
those estimates. Management believes that its estimates are reasonable.
Concentrations of Credit Risk
Financial instruments, which potentially subject the Company to concentrations of credit risk,
consist principally of cash. The Company generally maintains its cash balances at one
financial institution. At times, such investments may be in excess of the Federal Deposit
Insurance Corporation limit of $250,000. At December 31, 2008, no cash investment account was
in excess of the insured limit.
The Company had $0 gross revenue for the period ended December 31, 2008
Advertising and Promotions
Advertising and promotions are expensed as incurred and included in operating expenses. For
the period ended December 31, 2008 advertising and promotion
expenses were $0.
Income Taxes
The Company follows the liability method of accounting for income taxes in accordance
with SFAS No 109, Accounting for Income Taxes. Under this method, deferred income taxes
are recorded based upon the differences between the financial reporting and tax bases of
assets and liabilities and are measured using the enacted tax rates and laws that will be
in effect when the underlying assets or liabilities are recovered or settled.
Valuation allowances are established when necessary to reduce deferred tax assets to the
amount expected to be realized
7
HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 2: Commitments and Contingencies
On February 6, 2008, prior to the inception of HCA, the current management of HCA negotiated
and signed a three year agreement with Colonial Consulting Group ("Colonial") where Colonial
would perform certain consulting and business development services for HCA Under the terms
of the agreement, Colonial will be issued 60,000 common shares of HCA and HCA will pay
Colonial the sum of $5,000 per month for the first six months of the contract for services
performed by Colonial. For the remaining six months of the year, HCA will pay Colonial $10,000
per month for services rendered. For the second and third years of the agreement, HCA will pay
Colonial $15,000 and $20,000 per month, respectively for services rendered. Over the term of
the agreement, Colonial has the option to receive an equivalent portion of common stock in
place of payment. In addition, HCA will pay Colonial twenty five cents per prescription for
all business placements in HCA's market sectors Colonial is also entitled to a finder's fee
equal to five percent of invested money for any additional capital Colonial secures in HCA's
interest. Colonial may also acquire the equivalent of five percent of the finder's fee in
common stock at the initial rate of fifty cents per share
Note 3: Executive Compensation
The Company entered into formal employment contracts with its senior officers. These contracts
commenced October 1, 2008 and expire after four years. Prior to October 1, 2008, management
has estimated an amount that the officers earned on a monthly basis and has accrued the
officers' salaries to date in the financial statements. The officers began the process of
developing a business plan for the company in October 1, 2007; therefore, management has paid
or accrued fifteen months of officers' salaries Officers' salary expense for the period of
inception through December 31, 2008 was $465,000, which includes $369,500 of accrued
officer's compensation expense and $95,500 of payments to officers since inception. The Board
of Directors of HCA, at a board meeting held March 17, 2009, unanimously voted to defer the
accrued salaries due to officers. The board will reinstate the deferred accrued salaries of
the officers only when HCA's cash flow turns positive. The following summarizes the executive
compensation to senior management:
8
HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Sekulski
Drucker
Goldberg
Total
Accrual for services through 3/31/08
$
120,000
$
30,000
$
60,000
$
210,000
Accrual for services 4/1 - 6/30/08
15,000
15,000
15,000
45,000
Accrual for services 7/1 - 9/30/08
15,000
15,000
15,000
45,000
Accrual for services 10/1 - 12/31/08
90,000
30,000
45,000
165,000
Total officers' compensation
expense inception through December
31, 2008
$
240,000
$
90,000
$
135,000
$
465,000
Payments for services 2/26 - 3/31/08
$
27,000
$
—
$
5,000
$
32,000
Payments for services 4/1 - 6/30/08
12,500
—
—
12,500
Payments for services 7/1 - 12/31/08
50,000
1,000
—
50,000
Total payments for services
inception through December 31, 2008
$
89.500
$
1,000
$
5.000
$
95,500
Founders' service expense
$
950
$
300
$
50
$
1.300
Founders' shares for services
9,500,000
3,000,000
500,000
13,000,000
Note 4: Loan with LTC Specialists
In September 2008, HCA loaned $140,000 to Long Term Care Specialists, LLC
("LTC"), a New Jersey based limited liability corporation in the pharmaceutical
sales business. No interest was accrued on these loans HCA has received
information that LTC has ceased operations due to its continued inability to meet
its commitments. It is apparent that HCA's loan receivable from LTC is
uncollectible. Therefore HCA will apply its loan payable of $34,286 to LTC
against the $140,000 loan receivable resulting in a write-off of $105,714.
Note 5: Related Party Payables
HCA has loans with certain officers of the Company As of December 31, 2008 the
balance of these loans was $5,101. These loans do not bear interest.
Note 6: Stockholders' Equity
On
February 26, 2008, the date of inception, 520,000 shares were issued for cash.
On February 26, 2008, an additional 50,000 shares were issued for cash. On
February 29, 2008, an additional 20,000 shares were issued for
cash. These three
private placements raised a total of $35,000.
9
HEALTHCARE CORPORATION OF AMERICA and SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Additionally,
on March 31, 2008, 13,000,000 shares were subscribed as founders' shares at a
value of $1,300, and 115,000 shares were subscribed in exchange for services rendered, valued at
$57,600. Related capitalized costs of $42,233 were designated as subscriptions receivable at
March 31, 2008. For the nine months ending December 31, 2008, all of the previously
capitalized costs were expensed for consulting services performed.
On
July 3, 2008 25,000 shares of common stock were issued for cash. On August 28, 2008,
400,000 shares of common stock were issued for cash. These two stock issuances raised a total
of $212,500
Note
7: Related Parties
Gary Sekulski and Jan Goldberg have been officers of HCA since its inception and held
officer positions at LTC until October 2008 when they terminated their employment.
LTC had a consulting arrangement with certain officers of HCA and Colonial whereby
services were provided to LTC in 2008 for a fee. In accordance with this arrangement, this
fee was paid directly to the officers of HCA and to Colonial who performed the consulting
work.
10
EXHIBITS
3.1
Healthcare Corporation of America Certificate of Incorporation
3.2
Prescription Corporation of America Certificate of Incorporation
3.3
Healthcare Corporation of America By-Laws
3.4
Prescription Corporation of America By-Laws
3.5
Colonial Consulting Group, LLC Agreement
5.1
Opinion of Joseph Drucker
6.1
Consent of Joseph Drucker (Included as part of Exhibit 5.1)
8.1
Agreement with Toms River School District*
9.1
Agreement with Phillipsburg School District*
*
To be  filed as an amendment